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Abstract
This dissertation presents the initial findings of the SYMBIOME project; which attempts to
combine the objective and subjective aspects of musculoskeletal pain to develop a prognostic
clinical phenotype. Chapter 2 presents a moderator analysis of functional outcomes (pain
interference and pain severity). Psychosocial moderators can affect the relationship between
biomarkers and pain. For pain severity, TNF-α, TGF-β1, and CRP were moderated by
employment status, pre-existing psychopathology, and sex. For pain interference, IL-1β,
cortisol, TGF-β1, CRP, and IL-6 were moderated by pre-existing pain, peri-traumatic fear,
region of injury, and peri-traumatic stress. Chapter 3 presents a latent growth curve analysis
in determining the recovery trajectories of acute non-catastrophic musculoskeletal pain in the
context of pain interference and severity over the course of 12 months. For pain interference,
3 distinct trajectories emerged: rapid recovery, delayed recovery, or minimal/no recovery.
Pain severity favored a 2-trajectory model with rapid recovery or minimal/no recovery.
Classification of recovery group depended on both baseline symptoms and relative rate of
symptom decline. Recovery outcomes appeared to stabilize after a period of 3 months.
Chapter 4 presents latent class analysis and growth mixture modeling as applied to a panel of
8 biomarkers (TNF-α, IL-1β, IL-6, CRP, IL-10, cortisol, BDNF, and TGF-β1). These
markers may have the potential to discriminate between functional recovery outcomes.
Using these markers, 3 meaningful groups or classes were identified. These groups could be
adequately defined by using only 3 of the 8 markers (IL-1β, BDNF, and TGF-β1) where
classes were organized by low concentration of markers in serum, average concentration, or
high concentration of BDNF and TGF-β1. Those with high concentration of BDNF/TGF-β1
were more likely to score higher on self-report measures of pain and disability in their 6month outcomes. These results support the claim that physiological factors are tied to pain
through more than simple bivariate relationships. The context of the musculoskeletal trauma,
both personal and social, can affect the behavior of biological systems.
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Summary for Lay Audience
Pain is a complex process that occurs in our body. It involves psychology, genetics, and a
combination of the immune, nervous and endocrine systems. Short-term pain is important
because it helps us survive. However, when something goes wrong in one of those systems,
it can become a long-term problem. As pain goes on, it begins to affect the quality of life.
For the 20% of Canadians who struggle with chronic pain, everything begins to suffer
including health, finances, relationships, and work. Because pain is such a personal
experience, it is very difficult to understand and treat.
The SYMBIOME project stands for the SYstematic Merging of BIOlogy, Mental Health,
and Environment. The purpose of this project is to understand how pain develops over time.
After a traumatic accident or injury, people are invited into this year-long study. By using
questionnaires and collecting tissue samples, we have monitored their recovery. After one
year, some people fully recover while others develop chronic pain. When we compare the
mental and physical changes that occur between these people, it helps us understand how
pain becomes chronic. Your work status, education level, mental health, and physical
injuries all contribute to how your body deals with trauma. These factors can influence your
healing responses in a way that either increases or decreases your levels of inflammation and
stress in the short-term. In the long-term, it may also affect your ability to recover as people
tend to recover in 1 of 3 ways. Some people recover quickly and are functioning normally by
6 months. Some are delayed in their recovery but still reach normal function. And some
people still struggle with pain and disability even after 12 months. Analyzing various groups
of blood proteins may also shed some light on who tends to recover and who does not. With
this information, it will be possible to develop new treatments that can help people who
suffer from chronic pain. It may also help us treat pain in unique ways before it has a chance
to become a chronic problem.
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Preface
Dear Reader,

This thesis is being submitted during a turning point in modern history as we are currently in
the midst of an unprecedented health crisis. Due to the gravity of this event, I do not believe
it to be out of place to say a few words here for the sake of posterity.

This dissertation was completed shortly after the World Health Organization declared the
novel coronavirus (COVID-19) a pandemic on Mar 11, 2020. Many countries around the
world are struggling to survive as hospitals are being overrun. The infection continues to
spread at an alarming rate and resources are quickly being depleted. Governments are calling
for former healthcare workers to come out of retirement and companies are being asked to
repurpose their production facilities to meet the increasing demand for medical supplies.
Thousands of people have already succumbed to this virus and this number increases by the
day. Non-essential businesses have been forced to shut down and a nationwide protocol of
self-isolation and social distancing has been put into effect.

We are still in the early days of this pandemic, but I have already seen some of the extremes
of human nature. People have tried to hoard supplies and some refuse to isolate or
quarantine themselves. Some are in complete denial of this entire situation and insist on
indulging in their regular social pleasures despite the risk of infecting others. This has
become a problem among so many that the government has had no choice but to make
isolation a legal obligation. But then there is the other extreme. I have seen acts of heroic
courage as healthcare workers voluntarily put themselves in harm’s way for the sake of those
who suffer and for those who are still unaffected. Thousands of retirees have answered their
government’s call to enter the fray and support their colleagues. Teachers and parents have
demonstrated incredible compassion and resourcefulness as they continue to find ways to
educate and provide for the younger generations. Countless volunteers have arisen to support
frontline workers, employees work tirelessly to keep essential services running, and as
scientists are toiling to develop a vaccine, they are volunteering themselves as test subjects to
ensure its safety.
xiii

Although the world is trying to remain optimistic, it is uncertain how this will all end. Our
lives have been disrupted in ways we could never have imagined, and this test has only
begun. But even as I write this, I am reminded of a message written by a child on the
sidewalk: “Stronger together”. We may not have seen the worst of this crisis, but our hope is
greater still. People have united under these dire circumstances to work together, suffer
together, cry together, and fight together. The world, it seems, has decided to teach us all a
very important lesson. It is my sincere hope that the world in which you are reading this is
better because we have learned it.

With hope,

Joshua Lee
“I remain confident of this: I will see the goodness of the Lord in the land of the living.”
–Psalm 27:13
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Chapter 1
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Introduction

1.1 Preamble
The focus of this dissertation is to explore the biopsychosocial mechanisms which drive
the transition from acute to chronic pain in non-catastrophic musculoskeletal trauma.
The exploratory studies presented herein may help to characterize the complexity of pain
to inform future research targeted towards prognostication and early intervention. The
following introduction provides background information that will be necessary to
understand relevant details behind each of the subsequent chapters. It will outline the
burden of chronic pain and pain management, briefly describe the psychological and
physiological processes of pain, and identify relevant dimensions for testing.

1.2 The Burden of Chronic Pain
Although pain is an important mechanism for survival, it is the persistence of pain that
has a universal impact on our quality of life. Pain is by no means a stand-alone issue as it
often carries financial, clinical and social consequences1. The effects of chronic pain are
far-reaching as those affected also tend to struggle with depression, isolation, anxiety and
anger; which, in turn, have detrimental effects on personal relationships and vocational
roles1, 2. Taking into account both direct and indirect costs, the economic burden of pain
has reached a staggering $125 billion per year in the US alone2. Currently, chronic pain
affects 20% of all Canadian adults with an increasing prevalence in our aging population
that exceeds even such well-known conditions as diabetes mellitus and asthma2.
Medical interventions such as opioid drugs have seen a 347% increase in therapeutic use
in the USA3. This, however, is only a temporary measure as studies have shown that
opioids seem to be ineffective as a long-term solution to chronic, non-cancer pain;
especially with the risk of complications such as tolerance, addiction and abuse4, 5.
Furthermore, studies have shown that patients taking opioids were also susceptible to
more severe pain resulting in a greater reliance on health care compared to patients who
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were not taking opioids6. This myriad of complications is due, in part, to the complexity
of chronic pain. Existing at the nexus between biology, mental health, and environment,
pain has proven to be resistant to traditional medical and pharmaceutical treatments that
seek to eliminate symptoms 7. In the past, pain was regarded as the fifth vital sign, which
created an increased emphasis on treating pain intensity 8. This precipitated a program of
management whereby opioid treatments were disproportionately prescribed in order to
adequately address symptoms 9. Treating patients based on pain intensity has not
increased the quality of pain management 10, but has instead contributed to a crisis of
opioid-related overdose and death 11. Although much of the research in the fallout of this
crisis has been directed towards reducing opioid use 12, research has begun to make the
shift towards a more circumspect approach to pain.

1.3 Barriers to management
Despite the ongoing research in the field, the nature of pain is still fairly misunderstood
and a number of professional organizations have agreed that the best course of action is
to approach this issue from a multidisciplinary perspective 2, 13, 14. Studies performed by
Choinière et al13 have provided a fairly recent picture of the issues surrounding pain
management for people attempting to access multidisciplinary pain treatment facilities
across Canada. Their findings have indicated that some clients were placed on wait-lists
for months, even years before they were finally admitted to one of these facilities.
Additionally, for many of these clients, the natures of their specific clinical needs were
unclear and therefore, not adequately defined 2, 13, 14. Since pain is both a sensory and
emotional experience, it is highly variable between individuals15; which is perhaps what
contributes to a lack of concrete, generalizable strategies for pain management and
treatment. It may also explain why painkillers only function as an effective “magic
bullet” in a select few populations of people.

Within the rehabilitation community, there is a wealth of literature that documents the
psychological experiences of people who suffer from chronic pain. Although the validity
of these studies is not in question, pain is a subjective experience and has thus remained a
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fairly controversial condition 16. This negativity is quickly transmitted to the public
where it develops into stigmatization and stereotyping of individuals who suffer from
chronic pain 17. This has proven to be a difficult barrier to overcome as the concrete
presence of pain is contested by co-workers, communities, friends, and even family 18.
As a result of this pervasive societal doubt, people with chronic pain experience a
substantial decrease in both self-efficacy and willingness to seek treatment 18, 19. From a
biological standpoint, pain has become a well-established subject through intense and indepth study. Current theories in Systems Biology suggest that pain is the result of a wellorchestrated balance between the nervous, endocrine, and immune systems. However,
when one or more of these systems fails to resolve itself, the pain response (which
normally promotes survival) falls into discord and becomes a chronic problem 20.

1.4 A Biopsychosocial Approach
With pain management becoming such a complex problem, researchers have begun
investigating mechanisms that focus on the activity of entire systems, rather than specific
areas. Although the development of drug targets still continues, there have been an
increasing number of studies devoted to the understanding of structural and functional
changes in the brain. This is of particular importance as pain involves a number of
cognitive processes which are intimately linked with the perception of noxious stimuli.
Over the years, a number of studies which have employed non-invasive brain imaging
techniques have discovered a series of changes which occur in people who suffer from
pain. While global functioning of the brain is still being defined, the involvement of
higher neurological processes in chronic pain is undeniable.

One of the earliest accounts of pain control residing in the brain comes from surgical
reports of soldiers on the battlefield. In 1946, Beecher published a number of intriguing
findings from his experiences with soldiers that have suffered major wounds including
compound fractures of lower limbs and penetrating wounds to the chest and thorax 21. It
was found that most of the severely wounded, but mentally alert soldiers, declined the
offer of pain relief therapy upon admission to an army hospital. This was described as a
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“puzzlingly low incidence of pain”. Beecher goes onto describe how as with athletes
who do not feel pain till after the competition, it is not uncommon for wounds received
during fighting and anger to go unnoticed. Alternatively, it was suggested that being
severely wounded represents an escape from all the horrors of the battlefield; which
resulted not in the absence of pain, but the dismissal of its presence. In other words,
strong emotional responses have the capacity to modulate pain. Additionally, Beecher
criticized the automatic administration of morphine under the assumption of pain, rather
than actual need. Soldiers experiencing excitement or hyperactivity upon admission were
calmed significantly upon receiving a sedative, rather than an analgesic. It was also
noted that small doses of sedative given in combination with small doses of analgesic
provide both the mental depression and pain depression that the soldier actually needs.
This treatment was much more effective than large doses of either treatment given
individually.

Building upon years of foundational research in pain perception and emotional
regulation, Melzack proposed the Neuromatrix theory 22; that consolidated the pain
experience into three different but integrated systems of mental functioning: cognitiveevaluative (attention or anticipation of a noxious stimulus), sensory-discriminative
(intensity and location of a particular nociceptive input), and motivational-affective
(emotional responses such as anxiety or fear). This revolutionary model depicted the
formation of a “pain experience” that is specific to each individual and is dependent upon
both innate and experiential information. Melzack was one of the first to elaborate on the
concept that pain was more than a mere reflexive response to certain sensory inputs
alone.

1.5 Stress-system reactivity
The Hypothalamic-pituitary-adrenal (HPA) axis, connects cognitive impulses in the brain
with endocrine glands and hormonal control mechanisms in the body 23. This
neuroendocrine stress pathway represents an emotional nerve center for chronic pain,
anxiety and depression 24. Normally during stress, HPA axis activity involves the
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hypothalamic release of corticotropin releasing hormone (CRH), which acts on nearby
structures such as the locus coeruleus (LC - a brainstem nucleus and primary site for
noradrenaline synthesis) the amygdala, and the pituitary 25. Once it stimulates the
pituitary, adenocorticotropic hormone (ACTH) is released into the bloodstream 24, 25.
ACTH causes the production and release of glucocorticoids (GCs) from the adrenal
cortex to modulate immune responses, increase blood glucose, elevate blood pressure and
activate the CNS 25, 26. GCs stimulate the amygdala to release CRH, which is linked to
elevated anxiety and fear 27. Cortisol, a steroid hormone, is one of the primary GC
products of the human HPA axis activity and is increased during both chronic and
experimentally-induced pain 28. Early-life stress also has long-lasting consequences for
HPA axis activity. A recent review suggests that early-life adversity is linked to a longterm hypersensitivity to stress, elevated GCs and increased depression and anxiety-like
behaviors 29. Consistently high levels of GCs are potentially damaging to the
hippocampus as they reduce its neurological structure 30 and prevent plasticity 31. One of
the primary ways this is thought to occur is through a reduction in brain-derived
neurotropic factor (BDNF). This key protein, which is related to nerve growth factor
(NGF), is active in the cortex and hippocampus and is vital for neuronal plasticity and
long-term memory formation 32. Reductions in hippocampal BDNF have been implicated
in experimental pain 33, stress 34, and major mood disorders 35. These changes suggest
that early-life trauma, chronic pain and stress may prevent appropriate physiological
responses to stressors later in life.

1.6 Immunity and pain
There is a significant link between the nervous system and the immune system especially
in response to tissue damage and repair. The body's innate immune cells respond to injury
with an inflammatory response that activates pain pathways. Infiltration of inflammatory
cells, as well as activation of resident immune cells in response to nervous system
damage, leads to subsequent production and secretion of various inflammatory mediators.
Soluble mediators (particularly cytokines and chemokines) released by immune and glial

5

cells act on nociceptors (nerve fibers responsible for transmitting noxious stimuli),
increasing synaptic strength, modulating sensitivity, and sensitizing primary afferents 36.

Once released, cytokines drive inflammation and are capable of influencing cell
differentiation, gene transcription, and even cell survival 37, 38. They can bind to specific
receptors with such potency that only a handful of receptors need to be activated in order
to initiate a massive signaling event 39. Some of the most well-studied examples of proinflammatory cytokines are Tumor Necrosis Factor alpha (TNF-α), Interleukin-1 beta
(IL-1β) and Interleukin-6 (IL-6). These cytokines function synergistically and are
substantially elevated peripherally and centrally during injury, inflammation, and chronic
pain 40. They are extensively involved in the development of hyperalgesia
(hypersensitivity to pain) and allodynia 41-43, generation of noxious nerve transmissions
44-46

, prolonging pain sensitivity 40, 47, and neural degeneration and remodeling 48, 49.

Anti-inflammatory cytokines such as Interleukin-10 (IL-10) are crucial regulators of pain
development. IL-10 50 is a potent inhibitor of TNF-α, IL-1β, and IL-6 and it has been
recognized for its ability to counter the sensitizing actions of the pro-inflammatory
cytokines 51, 52. These cytokine responses have been extensively studied in multiple
animal models of injury, stress and chronic illness, and many of these observations have
been verified in humans (reviewed in 53, 54).

1.7 Chapter overview
This dissertation represents the initial findings of an ambitious exploratory study to
investigate the mechanisms that contribute to the transition from acute to chronic pain.
Since pain is very much an intersectional phenomenon between psyche and soma, the
overarching theme throughout this body of work is an emphasis on deep clinical
phenotyping. We have chosen to operate under the assumption that the body in pain is a
complex system that demonstrates emergent properties that cannot be explained by single
subsystem functions alone. To that end, the core of this dissertation will be presented in
3 distinct parts.
6

The aim of chapter 2 is to identify relationships between blood-based biomarkers and
psychosocial dimensions of functioning. This provides a more inclusive look at
physiological stress and immunity in an effort to go beyond simple bivariate relationships
between biomarkers and pain. In this chapter, we outline an exploratory moderator
analysis and hierarchical regression to find meaningful associations between cytokines
and person-level variables such as sex, stress, fear, socioeconomic status, pre-existing
comorbidity, and location of injury.

The aim of chapter 3 is to provide a longitudinal model of pain progression and recovery
over the course of 12 months. Using latent growth curve modeling, statistically
meaningful trajectories of recovery are identified in the context of both pain interference
(a.k.a. functional disability) and pain severity (a.k.a. pain intensity). With pain
interference as the primary functional outcome, people fall into 1 of 3 groups (or
“recovery classes”) where they demonstrate either a rapid recovery, delayed recovery, or
minimal/no recovery by 12 months. With pain severity, people tended to fall into 1 of 2
groups where people either had a rapid recovery or minimal/no recovery. This work falls
in line with previous studies of recovery trajectory modeling.

The aim of chapter 4 is to explore the potential of biomarkers to be used as prognostic
tools for functional recovery outcomes. We introduce a panel of 8 different biomarkers,
each with a previously identified association with pain. Using a similar analysis to
chapter 3, latent class analysis and growth mixture modeling are used to identify 3
statistically meaningful classes based on biomarker concentration (low, average, and high
concentration). For the sake of parsimony, this model is adequately represented by 3 of
the 8 markers including IL-1β, BDNF, and TGF-β1. Although recovered groups do not
tend to differ in their biomarker concentrations, those with persisting pain and disability
may have higher levels of BDNF and TGF-β1 present in serum.

The objective of the overall SYMBIOME project is to use rigorously collected data and
advanced longitudinal modeling techniques to identify and explore biopsychosocial

7

pathways of biological and cognitive functioning that can explain the transition from
acute to chronic musculoskeletal pain. Also, by connecting the more personal indices of
pain with biological mechanisms, we may gain a deeper understanding of this truly
unique experience while identifying novel therapeutic targets. It is our hope that in doing
so, we will provide biological evidence for the subjective, lived experience.
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Chapter 2

2

An exploration of blood marker-x-environment
interaction effects on pain severity and interference
scores in people with acute musculoskeletal trauma

2.1 Introduction
Pain is a complex experience that goes beyond simple sensory information. The
neuromatrix model suggests that pain is not just a physical response. Through a
combination of sensory, affective, and cognitive inputs, pain is the experience that is the
end-result of a determination of actual or potential threat or harm 1. The theory that pain
goes beyond simple physical dimensions is also illustrated in the diathesis-stress model 2;
which suggests that certain psychosocial or physiological elements may render an
individual more vulnerable to pain in the event of trauma. Due to the multifaceted nature
of this experience, it is notoriously difficult to diagnose and treat 3. Within the
rehabilitation community, there is a wealth of literature that documents the psychological
experiences of pain. Although the validity of these studies is not in question, pain in
humans is measured largely through subjective self-report and has thus remained a highly
debated condition 4.

From a biological standpoint, current theories in systems biology suggest that pain is the
result of a well-orchestrated balance between the nervous, endocrine, and immune
systems. The physiological stress response represents a powerful link between cognitive
perception and biological action. A crucial regulator of this response is the
Hypothalamic-pituitary-adrenal (HPA) axis, which connects cognitive impulses in the
brain with key endocrine glands in the body 5. This pathway incorporates such finelytuned control mechanisms that even brief, experimentally-induced stress is sufficient to
alter pain sensation and cause allodynia in healthy people 6. Cortisol, a steroid hormone,
is the primary product of HPA axis activity and people with either chronic or
experimentally-induced pain show changes in cortisol production 7. Another integral
component of the pain experience is the involvement of the inflammatory response.
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Inflammatory proteins such as c-reactive protein (CRP) have been implicated in
modulating pain sensitivity and have been linked to other major health conditions such as
diabetes, asthma and cardiovascular disease 8. Other examples of inflammatory proteins
in pain are pro-inflammatory cytokines Tumor Necrosis Factor alpha (TNF-α),
Interleukin-1 beta (IL-1β) and Interleukin-6 (IL-6). These cytokines function
synergistically and are substantially elevated during injury, inflammation, and chronic
pain 9. They appear to be involved in the development of hyperalgesia and allodynia 1012

, generation of noxious nerve transmissions 10, 13, 14, prolonging pain sensitivity 9, 15, and

neural degeneration and remodeling 16, 17. Anti-inflammatory cytokines Interleukin-10
(IL-10) and Transforming Growth Factor-beta (TGF-β1) also appear to play critical roles
in pain development. Both IL-10 18 and TGF-β1 19 have been recognized for their ability
to counter the pain-inducing actions of pro-inflammatory cytokines 20, 21. The pain and
sensitivity brought about by these proteins is relayed from the peripheral afferents to the
spinal dorsal horn by factors such as brain-derived neurotrophic factor (BDNF); which is
an essential neuropeptide involved in nerve growth, plasticity and sensitization 22.

As mentioned previously, the existence of pain does not rely solely on biological
mechanisms. There are many examples of pain that exist in the absence of any obvious
tissue damage or pathology 23. There is enough research now to suggest that many
chronic pain syndromes stem from a phenomenon known as sensitization; which involves
dysregulation of the neural activity involved in pain perception 23, 24. Many of the neural
pathways of pain are shared by mood, depression, anxiety and fear, which are influenced
by a variety of psychosocial variables 24. Studies have demonstrated that socioeconomic
status (SES) can affect levels of pain perception, where those with lower SES tend to
report higher levels of pain intensity25. Even with the same level of pain intensity, those
with lower SES may report anywhere from 2 to 3 times more perceived disability
compared to those in a higher socioeconomic bracket 26. Combining both the internal
physiology and the external environment, pain is truly a complex phenomenon that
requires balance between each system involved. When one or more of these systems fails
to resolve itself, the whole response falls into discord and can become a chronic problem
27, 28

. What triggers this dysregulation, however, is still a topic of debate as the
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transitional mechanisms between acute to chronic pain involves multiple domains that
have not been definitively identified in humans 29, 30. Current research emphasizes an
interdependence of biopsychosocial domains such that pain may result from a
combination of underlying biological vulnerability and/or induction via psychological or
social triggers 31. Prior work in the field of biomarkers indicates, for example, that
processing of nociceptive information may occur through different receptors or pathways
in males and females such that the magnitude of association between certain markers and
pain could be moderated by sex 32, 33.
Therefore, the purpose of this paper was to add to this pool of knowledge by exploring
potential interaction effects between relevant psychosocial variables and physiological
mechanisms of pain (via biomarkers of stress, inflammation, and pain sensitivity) and
perceived levels of pain within the acute stages of post-traumatic musculoskeletal injury.

2.2 Methods
2.2.1

Participant recruitment

Data for this study were drawn from the SYMBIOME (Systematic Merging of Biology,
Mental Health and Environment) longitudinal cohort and data-banking study
(clinicaltrials.gov ID no. NCT02711085). Appendix C outlines the overall data
collection process for the study. Eligible participants were those presenting at an Urgent
Care Centre in Ontario, Canada for reasons of non-catastrophic MSK trauma. Noncatastrophic referred to those with injuries that did not require surgery or hospitalization.
Eligible participants presented to the centre within 3 weeks of the injury, were at least 18
years old, and could speak and understand conversational English. Study participants
were admitted with injuries from a motor vehicle collision, fall/slip injuries, impact from
another person or object, awkward lift/twist, or other context-specific causes that led to
non-catastrophic (no surgery or inpatient admission required) injuries of the MSK
system. Participants were free to indicate multiple areas of involvement. Participants
were also asked to report whether they were taking any medications during the time of
intake into the study. Excluded from this analysis were those with significant systemic or
18

neuromuscular comorbidity that would have been expected to affect physiological
response to trauma or recovery, including active cancer, rheumatic conditions or other
systemic inflammatory processes, significant organ disease, those with
immunocompromised conditions (e.g. HIV/AIDS) or taking immunomodulatory drugs
(e.g. high-dose steroids or disease-modifying anti-rheumatic drugs). Pregnancy was not
an exclusion criterion, but no participant was pregnant during the study.

After being medically cleared and discharged, interested participants gave permission for
a member of the research team to describe the study, answer questions, and enroll prior to
leaving the hospital. Participants were provided a package of self-report questionnaires
and serum samples were collected on-site from the median cubital vein by a phlebotomytrained member of the research team. The questionnaires included tools to measure pain
severity (Brief Pain Inventory - BPI, severity subscale 34), pain-related functional
interference (BPI, interference subscale 35), and several questions pertaining to patient
metadata (age, sex, work status, educational attainment, medicolegal status, household
income and family status), and pre-existing health conditions (medications,
comorbidities) variables.

The BPI is one of the most widely used pain scales globally 36

and has adequate evidence of validity across many clinical populations including
musculoskeletal pain 37. Psychological and social elements have also been identified as
influential outcomes in musculoskeletal trauma 38. Key mental health dimensions
including depressive symptoms and post-traumatic distress were captured in the
SYMBIOME cohort. All participants provided informed, written consent prior to
participation, and the study was approved by the local institutional review board prior to
initiation.

2.2.2

Capture and analysis of serum biomarkers

The biomarkers chosen for this study are those associated with stress, pain, sensitivity,
and inflammation (Table 2). Eight markers were chosen for this analysis: BDNF, TGFβ1, CRP, TNF-α, IL-1β, IL-6, IL-10 and cortisol. Analyte concentration in plasma (ng/g)
was assayed using multiplexed biomarker immunoassay kits according to manufacturer
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protocol for BDNF (Human Premixed Multi-Analyte Kit, R&D Systems Inc. cat. no.
LXSAHM), TGF-β1 (TGFΒ11 Single Plex Magnetic Bead Kit, EMD Millipore cat. no.
TGFΒ1MAG-64K-01), IL-1β, IL-6, IL-10 and TNF-α (Human High Sensitivity T Cell
Magnetic Bead Panel Multiplex Kit, EMD Millipore cat. no. HSTCMAG-28SK). A
BioPlexTM 200 readout System was used (Bio-Rad Laboratories, Hercules, CA) with
Luminex® xMAPTM fluorescent bead technology (Luminex Corp., Austin, TX). Levels
are automatically calculated from standard curves using Bio-Plex Manager software
(v.4.1.1, Bio-Rad). Cortisol (Cortisol Enzyme Immunoassay Kit, Arbor Assays cat. no.
K003-H1/H5), and CRP (C-Reactive Protein (human) ELISA Kit, Cayman Chemical
Company cat. no. 10011236) were assayed following manufacturer protocol for EnzymeLinked Immunosorbant assay (ELISA). All assays were performed in duplicate with the
value for analysis being the mean concentration of the two. For the first 50 samples,
assays were also conducted on two separate aliquots from each participant to monitor
consistency in technique. Biomarker data were first explored for fidelity, removing any
concentrations that, after duplicate runs, were not detectable or out of range of the kit. As
correlations are sensitive to extreme values, we also identified any biomarker
concentration that was >3SD above or below the sample mean and removed it to avoid
spurious findings.

2.3 Analysis
Normality (skew and kurtosis) of biomarker data was statistically tested through
Kolmogrov-Smirnov tests, and data were centered about the mean and square-root
transformed where necessary. Descriptive statistics for the patient metadata were
explored descriptively (mean, median, range).

For the first pass analysis a correlation matrix was created to estimate the simple bivariate
associations between concentration of each of the 8 blood markers and scores on the two
primary outcomes (pain and interference subscales of the BPI). As an exploratory
analysis, the sample was then split into two sub-categories based on the level of
participant metadata being explored (e.g. male/female, young/old age, high/low SES).
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Where continuous data were used as a grouping variable (e.g. household income, body
mass index, age), either a median split was used, or in the case of household income, the
median Ontario income level as reported by StatsCan for 2016 of $80,000/year was used.
The operationalization for each level of independent variable along with their definitions
are outlined in Table 3. With the database split by level of moderator, bootstrapped
linear correlations were again conducted. Bootstrapping using the n=1000 random subselection procedure in SPSS provided 95% confidence intervals for each of the
correlation coefficients. Where the magnitude of correlation coefficient for one variable
was outside of the confidence intervals of its categorical counterpart, that metadata
variable was then retained for further analysis. Only those metadata variables for which
each level included more than 10% of the total sample (minimum n = 8) were explored.

More rigorous exploration of potential moderators from the prior step occurred through
hierarchical multiple regression analyses. Independent variables were (in order of entry):
the individual biomarker for which the interaction may have been present, the metadata
variable, and then the marker x metadata variable interaction term. After ensuring that
assumptions of regression were satisfied, moderator analysis was conducted according to
the methods previously described by Kraemer and colleagues 39. This included centering
the biomarker data on its mean to avoid multicollinearity and over-fitting of the models.
Where the addition of the interaction term led to a significant change in F (significant
improvement in model fit) after first controlling for the biomarker and metadata variable,
the metadata variable was deemed a moderator of the association between biomarker and
clinical pain or interference rating. If the inclusion of the interaction term led to
significant change in model fit while the two base variables did not, the metadata variable
was deemed to fully moderate the association. Where the interaction term was significant
in addition to one of the two base variables, the moderation was considered partial.
Appendix D depicts a simple schematic for moderator variables. All statistical analyses
were performed with IBM SPSS Statistics 25.0 software.
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2.3.1

Sample size estimation

Previous studies investigating biomarkers of pain performed by Cantón-Habas and
colleagues have calculated their sample size based on a small to moderate potential
correlation (r = 0.3) 40. A power analysis was conducted using G*Power v3.1 41
indicating that a total sample of 81 participants would be required to detect moderate
effects (f2 = 0.10) with β = 80% using multiple regression with α = 0.05.

2.4 Results
From 2016 to 2018, a total of n = 109 participants provided blood samples used in the
current analysis. Participant characteristics are reported descriptively in Table 1. When
grouped by region as axial (head, neck or back) or peripheral (upper or lower
extremities), 29.2% of the sample indicated axial injuries. Only 61.3% of participants
reported taking medications, and 21.3% reported taking one or more medications for pain
including NSAIDs, opioids, gabapentin, or pregabalin. Out of 109 participants, 3
participants were removed as all analytes were undetectable. Of the remaining 106
participants, some provided an incomplete data set as certain biomarkers were considered
out-of-range. The proportion of assays that led to out-of-range results for the biomarkers
were: IL-10 (3.7%), IL-1β (4.6%), TNF-α (2.8%), BDNF (0.9%), Cortisol (2.8%), TGFβ1 (0%), CRP (11.9%), IL-6 (11.9%). These values were >3SD beyond the mean and
removed from the analyses. The results of Kolmogrov-Smirnov testing on the remaining
data revealed significant deviation from normality in 6 of the 8 biomarkers, mostly due to
positive skew. A square-root transformation was therefore applied to all 8 markers that
significantly reduced the skew and saw all 8 markers achieve adequate normality for
correlational analysis. Medicolegal Status was excluded from moderator analysis due to
the number of participants involved in litigation on entry into the study (<3 weeks from
injury) being below 10% of the sample. All other metadata variables could be split into
two groups each of which included greater than 10% of the sample. Based on a priori
sample size calculations, this required each group to contain more than 8 participants.
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The first rows of Table 4 and 5 present the simple bivariate correlation coefficients
between the 8 biomarkers and 2 clinical outcomes. None of the biomarkers on their own
demonstrated a significant correlation with either BPI pain severity or interference. The
Tables also present the correlation coefficients when the sample was first split by level of
each of the 16 metadata variables. Bolded values are those that were explored through
formal regression-based moderator analysis based on the difference in magnitude of
correlation coefficient between the two levels.

2.4.1

Moderator analyses for Pain Severity

Results for the significant moderators are reported in Table 6A. Employment prior to
trauma (Employed for pay/not employed for pay) fully moderated the association
between TNF-α and pain severity, as the inclusion of the interaction term accounted for a
significant 4.4% of the total variance in pain severity (F(1, 90) = 4.39, p = 0.04) (Figure
1A). Pre-existing psychopathology (diagnosed yes/no) fully moderated the association
between TGF-β1 and pain severity (F(1, 91) = 7.95, p < 0.01) with the interaction term
explaining 8.0% of the total variance (Figure 1B). Sex (male/female) fully moderated
the association between CRP and pain severity (F(1, 86) = 5.98, p = 0.02), explaining
6.3% of the total variance (Figure 1C).

2.4.2

Moderator analyses for Pain Interference

Results for the significant moderators are reported in Table 6B. Reports of a pre-existing
pain condition (yes/no) partially moderated the effect of IL-1β on pain interference, as it
accounted for an additional 7.2% of variance beyond IL-1β alone (F(1, 89) = 6.88, p =
0.01). Inclusion of the interaction term accounted for an additional 6.9% (Figure 2A).
Peri-traumatic fear (frightened at the time of the traumatic event, yes/no) also partially
moderated the effect of IL-1β on pain interference, as it accounted for an additional 6.5%
of variance beyond IL-1β alone, F(1, 90) = 6.45, p = 0.01 and the interaction term
accounted for an additional 6.4% (Figure 2B). Region of injury fully moderated the
effect of cortisol on pain interference, as the addition of the interaction term accounted
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for 4.5% of the total variance, F(1, 90) = 4.30, p = 0.04 (Figure 2C). Region of injury
also fully moderated the effect of TGF-β1 on pain interference, as the inclusion of the
interaction term accounted for an additional 4.5% of the total variance, F(1, 92) = 4.37, p
= 0.04 (Figure 2D). Peri-traumatic stress (general, life stress prior to the event) partially
moderated the effect of TGF-β1 on pain interference, as it accounted for 8.9% of the total
variance alone, F(1, 91) = 8.91, p <0.01 and the interaction term explained an additional
4.4% (Figure 2E). Region of injury also fully moderated the effect of CRP on pain
interference, as the inclusion of the interaction term accounted for an additional 10% of
the total variance, F(1, 87) = 10.28, p < 0.01 (Figure 2F). Peri-traumatic fear partially
moderated the effect of IL-6 on pain interference, as it accounted for 5.5% of the total
variance alone, F(1, 91) = 5.30, p = 0.02 and the interaction term explained an additional
5.4% (Figure 2G).

2.5 Discussion
The purpose of this study was to determine whether various biological, psychological and
social factors were associated with immune and neurological biomarkers in
musculoskeletal trauma. The secondary purpose was to evaluate the extent to which
these factors moderated any associations between biomarkers and pain. Similar to other
research in the field of biomarkers, our study demonstrates the potential for psychological
and social variables to influence agents of immunity. Our results showed that TNF-α,
TGF-β1, and CRP form potentially meaningful associations with pain severity and IL-1β,
cortisol, TGF-β1, CRP and IL-6 form associations with pain interference (disability) but
only in the presence of important metadata variables. These associations were either
partially or fully moderated by factors such as employment status, sex, pre-existing
psychopathology, pre-existing pain, region of injury, peri-traumatic fear, and peritraumatic stress.

Unlike prior work in pain biomarkers, none of the biomarkers on their own revealed a
significant correlation with pain severity or interference. This is perhaps unsurprising as
many of the studies indicating elevated levels of biomarkers in humans are shown under
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chronic, not acute pain conditions 42. It is also important to note that the present study
analyzed serum levels of stress and inflammatory biomarkers. It is possible that traumarelated inflammation and stress in the acute phase may have been localized to the site of
the injury. One of the few studies that measured biomarkers in acute pain and
inflammation was performed by Angst and colleagues via microdialysis to track tissuelevel cytokine changes after 24 hours 43. Experimentally-inflamed skin did not affect
TNF-α levels, but IL-1β, IL-10, and IL-6 were all significantly increased. They also
found that administration of 400mg of the non-steroidal anti-inflammatory drug,
ibuprofen, significantly increased heat and mechanical pain thresholds, while 800mg
caused a decrease in IL-1β and IL-6 levels in the tissue. The microassays, along with
experimental inflammation, both occurred in the thigh of their study participants which
may suggest that the detected increase in cytokines was due to the proximity of the
assayed tissues to the site of irritation.

The concept of external influences on biomarkers of stress and inflammation has been
studied previously in the context of pain. Sibille and colleagues compiled a “risk factor
composite” which included BMI, fibrinogen, CRP, and triglyceride levels 44. Their
results showed that generalized chronic pain was a significant predictor of this composite,
but it was also significantly influenced by factors such as age, sex, education level,
smoking habit, exercise, and alcohol consumption. Sterling and colleagues found that
CRP and TNF-α were significantly different between severity groups in whiplash. They
also showed that CRP was significantly different between acute and chronic phases of
whiplash. However, in addition to IL-1β, those authors show that biomarkers were not
significantly correlated with post-traumatic stress disorder or pain catastrophizing. In the
study, they suggest that inflammatory biomarkers may be more associated with pain and
disability rather than psychological constructs 45. Our findings seem to be in agreement
with previous studies in this area, however, we go on to suggest that the association
between biomarkers and pain may actually depend on the presence of certain
biopsychosocial factors.
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Pain severity showed significant associations with only 3 different biomarkers, and these
associations were dependent on specific variables. The relationship between TNF-α and
pain severity was dependent on employment status prior to the trauma. Prior work
suggests that inflammatory status can be influenced by productive activities such as
employment and in particular, volunteering, can reduce the systemic inflammatory profile
later in life 46. Along a similar vein of research, Steptoe and colleagues reported
differences in TNF-α and IL-6 blood levels between those in different grades of
employment (high, intermediate, and low socioeconomic class). Their results suggested
that intermediate grades have slightly elevated levels of TNF-α compared to high grade
employees 47. Results from the present study appear to agree with these findings as TNFα displays other potential dichotomous relationships with pain severity in the context of
return-to-work status, and with pain interference in the context of household income.
The relationship between TGF-β1 and pain severity was dependent on the presence or
absence of psychopathology. Previous studies have suggested that psychopathologies
such has depression and dementia involve a balance between 2 different classes of
cytokines and that the TGF-β family (which represent a group of regulatory cytokines)
can potentially influence this balance 48. Those diagnosed with major depressive
disorder, for example, have shown significant decreases in their TGF-β levels 49, and antidepressive treatments for this disorder are associated with an increase in TGF-β 50. With
its anti-inflammatory properties, TGF-β1 has also been identified for its potential to
influence key pathways associated with pain 51.

The relationship between CRP and pain severity seemed to be influenced by sex
differences. It has been shown previously that men and women present differently with
respect to pain. In osteoarthritis, for example, women experience a greater severity of
pain and disability, and they appear to display more pain-related behaviors as well 52.
These differences may also extend to the levels of CRP in the blood as mean
concentrations are also higher in females 53.
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Pain interference, or disability showed significant associations with 5 different
biomarkers, and once again these associations were dependent on the presence or absence
of certain metadata variables. The relationship between IL-1β and disability was
influenced by both pre-existing pain and peri-traumatic fear. Increases in IL-1β have
been associated with allodynia (a feature of pathological pain), neuropathic pain,
cognitive deficits and depression 54, 55. As a well-known pro-inflammatory cytokine, this
relationship has been fairly well-established in the literature so it comes as no particular
surprise. What is interesting however is that IL-1β has also been implicated in
conditioned fear memory 56 and enhancing the fear-learning response under stress 57.
These findings suggest that it is not unusual that IL-1β is influenced by both pain and
fear. Peri-traumatic fear also influenced the association between IL-6 and disability.
Like IL-1β, IL-6 is a pro-inflammatory cytokine that has also been shown to influence
fear conditioning 58 and fear memory 59, along with being a key regulator of pathological
pain states 60. Both IL-1β and IL-6 have been shown to be involved with anxiety and
fear-related pathologies such as PTSD and generalized anxiety disorder 61.

Another factor that appeared to be particularly influential in disability was the region of
injury. The location of the trauma, either axial (head, neck or back) or peripheral (limb
involvement), moderated the associations of cortisol, TGF-β1, and CRP with pain-related
disability. Previous studies have shown that traumatic injuries involving axial structures
result in more than twice the functional disability than peripheral injuries 62. This may
explain why the region of injury can influence these biomarkers of stress and
inflammation. Cortisol, a primary stress hormone, is regulated by circadian rhythms,
where dysfunctions in these rhythms have been associated with pain, fatigue, and coping
in non-specific low back pain 63. CRP has also been linked to chronic low back pain
along with insomnia, which is a key contributor to disability 64. With regard to TGF-β1,
more recent studies have begun to investigate its role as a potential target for preventing
degenerative disc disease, which can involve both the neck and back. It is has been
shown to activate genes related to tissue growth and repair in the intervertebral discs,
making it a potential therapeutic target in the future 65.
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The regulatory role of TGF-β1 appears to extend even further as peri-traumatic stress also
influenced its association with disability. Through a series of elegant experiments, Zhang
et al showed that chronic stress has an immunosuppressive effect which is modulated by
the TGF-β1 signaling pathway. A stress-induced imbalance of pro- and antiinflammatory mediators was restored by blocking this pathway 66. Taken together, each
of these studies, along with our findings suggest that both pain and disability are fairly
nuanced constructs that involve more than a simple binary association with immune and
neurological biomarkers.

Some limitations to the present study will be addressed here. First, blood was drawn
within the same time-frame that participants presented to the urgent care or emergency
medical centres. This represents an important potential confound as it did not allow for
consistency in sample collection times. Different biomarkers have known diurnal
variations in their activity and these variations could not be accounted for as extraction
occurred at various times throughout the day. Second, although we were able to
demonstrate moderator effects of different variables between biomarkers and pain, the
nature of these effects is still unknown. Based on an a priori sample calculation, we were
sufficiently powered to show moderate effects, but within a single variable, some of the
sample sizes may have been too small to detect the magnitude and direction of the
different associations. For example, the region of injury group was approximately
divided into 29.2% spinal and 70.8% peripheral injury. The medicolegal status group
was excluded for this exact reason, despite being a potentially relevant moderator.

In conclusion, we have presented an exploratory study that demonstrates the potential
involvement of biopsychosocial factors and their ability to influence the relationship
between biomarkers and pain. This was done in the context of non-catastrophic
musculoskeletal trauma using correlational analysis and regression. Our results show that
employment status, pre-existing psychopathology, and sex emerge as relevant moderators
of TNF-α, TGF-β1, and CRP respectively with regard to pain severity. Other factors
such as pre-existing pain, peri-traumatic fear, region of injury, and peri-traumatic stress
are relevant moderators of IL-1β, cortisol, TGF-β1, CRP, and IL-6 with regard to pain
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interference/disability. This study adds to a pre-existing body of knowledge that suggests
that the mere presence or absence of biomarkers is insufficient to adequately capture their
effects on pain as their activity may be contextual. Studies that do not take these
moderator variables into consideration may be at risk of underreporting the involvement
of stress and inflammation in pain. Future research may involve investigating the
downstream consequences of these psychophysical associations. Longitudinal studies
may provide some insight into which associations are relevant in predicting the
development of chronic pain in the future.
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Table 1 – Participant characteristics

Sample size

109

Mean Age

43.7 (±14.6)

Spinal injury

29.2%

Mean BMI

26.7 (±6.2)

Sex (% female)

57.7%

Mean pain severity (out of 10)

4.3 (±2.1)

Mean pain interference (%)

38.4 (±23.9)
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Table 2 – Relevant immune and neurological biomarkers
Type

Rationale

Pro-inflammatory

Increased during pain, generates

cytokines

hyperalgesia/allodynia, stimulates noxious

Biomarker
TNF-α, Il-1β, Il-6

signaling, prolongs pain sensitivity, contributes to
neural degeneration and remodeling, influences
long-term changes in neuronal signaling patterns
Il-10, TGF-β

Anti-inflammatory

decreased during pain, Inhibits TNF-α/Il-1β/Il-6,

cytokines

counter-acts pain sensitization activity of proinflammatory cytokines

BDNF

Secreted protein /

Associated with sensitivity, depression, and

neurotransmitter

anxiety. Facilitates interaction between
peripheral and central nervous system

CRP

Inflammatory peptide

Increased during major pathology such as
cardiovascular disease, diabetes, asthma.
Increased levels implicated in increased pain
sensitivity.

Cortisol

Steroid hormone

Primary product of HPA axis, associates with pain
and stress, elevated in pain and stress, influences
immune activity
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Table 3 – Psychosocial variables with binary category designation
Category designations
Metadata variable
Sex

Male / Female

Region of Injury

Spinal (head, neck, or back) / peripheral (limb
involvement)
>25.09 / <25.09 (since 25 indicates
“overweight”)

Body-Mass Index (BMI)

Employment prior

Employed / Unemployed for pay prior to
trauma

Return-to-work status (RTW)

Full return / Partial or no return to previous
employment
Involved / Not involved in litigation due to
injury

Medicolegal status

Post-Secondary Education

post-secondary / no post-secondary (postsecondary includes college, university, trade
school or other certification programs)
<$80,000 / >$80,000 (where $80,000
represents the Ontario median)
Present / Absent (any pre-existing condition
that has been formally diagnosed and/or is
being treated)
Present / Absent (any pre-existing condition
that has been formally diagnosed and/or is
being treated)
Yes / No (whether or not the participant was
frightened by the event)
Likely depressed / Not likely depressed (based
on meeting the depression threshold on the
PHQ-9 questionnaire)
<2 / ≥2 (general, pre-trauma life stress was
measured on a Likert scale where <2 indicates
little or no life stress)
Absent / present (either direct or indirect
exposure to abuse or neglect)

Household Income
Pre-existing Psychopathology

Pre-existing Pain

Peri-Traumatic Fear
Depression

Peri-Traumatic Stress

Any Adverse Childhood Experiences (ACE)
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Table 4 – Correlations of biomarkers with pain severity in the presence of moderators

Full sample (R (p))
Sex
Female
Male

Region of Injury
Spinal
Peripheral

BMI
≤25.09
>25.09

Employment Prior
Employed for pay
Not employed for pay

Return-To-Work Status
Full RTW
Partial or no RTW

Post-Secondary
Education
No post-secondary ed.
Post-secondary ed.
Household Income
<$80k
≥$80k

TNFα (97)

IL-10 (102)

BDNF (99)

IL-1β (94)

Cortisol (95)

TGFβ (97)

CRP (91)

IL-6 (94)

-0.05 (0.61)

-0.08 (0.77)

-0.04 (0.72)

-0.03 (0.77)

-0.05 (0.65)

-0.05 (0.66)

-0.09 (0.39)

-0.12 (0.24)

(56) -0.03 (-0.32,
0.25)
(40) -0.02 (-0.32,
0.30)

(53) -0.09 (-0.31,
0.12)
(39) -0.07 (-0.39,
0.25)

(58) 0.06 (-0.18,
0.30)
(40) -0.19 (0.48, 0.16)

(53) -0.07 (-0.36,
0.21)
(40) -0.01 (-0.23,
0.25)

(57) -0.02 (-0.29,
0.26)
(37) -0.15 (-0.45,
0.14)

(57) -0.01 (-0.25,
0.23)
(39) -0.18 (-0.50,
0.15)

(54) -0.30 (-0.52, 0.04)*^^
(36) 0.22 (-0.08,
0.46)

(56) 0.06 (-0.26,
0.37)
(37) -0.31 (-0.58,
0.01)

(24) 0.08 (-0.26,
0.37)
(73) -0.08 (-0.32,
0.16)

(22) -0.27 (-0.62,
0.06)
(71) -0.03 (-0.23,
0.16)

(24) 0.01 (-0.42,
0.49)
(75) -0.06 (-0.28,
0.18)

(21) 0.03 (-0.43,
0.48)
(73) -0.04 (-0.24,
0.16)

(22) -0.43 (-0.76,
0.04)*
(73) 0.05 (-0.18,
0.27)

(24) 0.02 (-0.39,
0.49)
(73) -0.05 (-0.26,
0.16)

(20) 0.14 (-0.31,
0.63)
(71) -0.16 (-0.37,
0.07)

(21) 0.06 (-0.49,
0.67)
(73) -0.17 (-0.39,
0.08)

(46) -0.09 (-0.43,
0.26)
(39) 0.01 (-0.29,
0.31)

(41) -0.17 (-0.42,
0.08)
(46) -0.01 (-0.24,
0.23)

(43) 0.02 (-0.28,
0.32)
(50) 0.03 (-0.24,
0.29)

(42) -0.18 (-0.45,
0.10)
(47) 0.16 (-0.10,
0.40)

(41) -0.13 (-0.42,
0.15)
(48) -0.04 (-0.33,
0.24)

(42) -0.12 (-0.39,
0.19)
(50) -0.01 (-0.31,
0.28)

(41) -0.05 (-0.36,
0.26)
(45) -0.07 (-0.35,
0.24)

(41) -0.22 (-0.53,
0.13)
(48) 0.06 (-0.27,
0.37)

(70) -0.20 (-0.40,
0.02)
(24) 0.28 (-0.13,
0.61)^^

(69) -0.05 (-0.24,
0.14)
(22) -0.04 (-0.44,
0.36)

(72) -0.08 (-0.31,
0.16)
(24) -0.03 (-0.47,
0.37)

(68) -0.03 (-0.22,
0.19)
(23) -0.24 (-0.58,
0.12)

(69) 0.08 (-0.15,
0.31)
(23) -0.20 (-0.56,
0.19)

(70) 0.05 (-0.17,
0.26)
(24) -0.35 (-0.68,
0.03)

(68) -0.14 (-0.34,
0.08)
(22) 0.01 (-0.42,
0.46)

(69) -0.15 (-0.41,
0.13)
(23) -0.04 (-0.44,
0.33)

(52) -0.25 (-0.47, 0.01)
(37) 0.16 (-0.18,
0.49)

(50) -0.16 (-0.41,
0.09)
(35) -0.02 (-0.28,
0.26)

(53) -0.11 (-0.35,
0.16)
(38) 0.08 (-0.24,
0.37)

(50) -0.12 (-0.37,
0.17)
(36) 0.08 (-0.20,
0.39)

(53) 0.03 (-0.20,
0.29)
(34) -0.09 (-0.44,
0.27)

(51) 0.04 (-0.22,
0.27)
(38) -0.13 (-0.41,
0.16)

(52) -0.18 (-0.40,
0.06)
(33) -0.02 (-0.41,
0.36)

(53) -0.18 (-0.48,
0.16)
(34) -0.04 (-0.37,
0.24)

(25) -0.01 (-0.54,
0.50)
(71) -0.07 (-0.27,
0.15)

(24) -0.18 (-0.53,
0.16)
(68) -0.05 (-0.25,
0.15)

(24) 0.18 (-0.19,
0.48)
(74) -0.09 (0.30, 0.14)

(25) 0.12 (-0.29,
0.50)
(68) -0.09 (-0.28,
0.12)

(22) 0.19 (-0.23,
0.59)
(72) -0.13 (-0.36,
0.11)

(24) -0.08 (-0.49,
0.35)
(72) -0.05 (-0.25,
0.17)

(21) -0.12 (-0.57,
0.34)
(70) -0.08 (-0.30,
0.15)

(22) -0.13 (-0.60,
0.28)
(72) -0.11 (-0.36,
0.16)

(46) -0.14 (-0.46,
0.17)
(47) 0.02 (-0.23,
0.27)

(45) -0.16 (-0.39,
0.07)
(45) 0.02 (-0.24,
0.28)

(48) -0.11 (-0.37,
0.14)
(47) 0.00 (-0.31,
0.30)

(45) -0.20 (-0.49,
0.11)
(45) 0.14 (-0.14,
0.39)

(45) -0.12 (-0.39,
0.20)
(46) 0.10 (-0.16,
0.35)

(47) -0.13 (-0.37,
0.13)
(46) 0.01 (-0.30,
0.29)

(43) -0.12 (-0.40,
0.21)
(46) -0.05 (-0.31,
0.25)

(45) -0.34 (-0.64, 0.03)*
(46) 0.02 (-0.33,
0.34)

Pre-Existing
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Psychopathology
Yes
No
Pre-Existing Pain
Yes
No

Peri-Traumatic Fear
No
Yes

Depression
Likely depressed
Not likely depressed

Peri-Traumatic Stress
Low stress (<2)
High stress (2 or more)

Any ACE
At least one
None

Any ACE (direct)
At least one
None

Any ACE (indirect)
At least one
None

(26) 0.16 (-0.20,
0.46)
(69) -0.10 (-0.39,
0.17)

(25) -0.24 (-0.49,
0.00)
(66) 0.02 (-0.19,
0.22)

(26) -0.18 (-0.62,
0.18)
(71) -0.01 (-0.25,
0.23)

(25) -0.33 (-0.62,
-0.02)
(67) 0.05 (-0.16,
0.28)

(25) 0.05 (-0.37,
0.47)
(68) -0.10 (-0.34,
0.15)

(26) -0.48 (-0.70,
0.17)*^^
(69) 0.10 (-0.12,
0.30)

(23) 0.02 (-0.36,
0.37)
(67) -0.15 (-0.38,
0.10)

(23) -0.29 (-0.78,
0.16)
(70) -0.05 (-0.33,
0.22)

(17) 0.41 (-0.06,
0.81)
(76) -0.11 (-0.34,
0.14)

(16) 0.19 (-0.20,
0.79)
(73) -0.12 (-0.32,
0.06)

(17) -0.13 (-0.57,
0.32)
(78) -0.04 (-0.25,
0.19)

(17) 0.23 (-0.21,
0.59)
(75) -0.10 (-0.29,
0.10)

(17) 0.25 (-0.16,
0.56)
(74) -0.06 (-0.29,
0.19)

(16) -0.33 (-0.70,
0.25)
(77) 0.00 (-0.19,
0.20)

(14) 0.07 (-0.41,
0.51)
(75) -0.11 (-0.34,
0.11)

(15) 0.27 (-0.64,
0.86)
(77) -0.20 (-0.43,
0.03)

(50) -0.17 (-0.45,
0.14)
(46) 0.08 (-0.24,
0.37)

(50) -0.17 (-0.40,
0.10)
(42) 0.05 (-0.21,
0.30)

(52) -0.05 (-0.30,
0.19)
(46) 0.01 (-0.31,
0.36)

(49) -0.15 (-0.41,
0.10)
(44) 0.14 (-0.12,
0.38)

(51) -0.02 (-0.30,
0.24)
(43) -0.08 (-0.39,
0.24)

(50) 0.03 (-0.23,
0.26)
(46) -0.14 (-0.39,
0.16)

(49) -0.17 (-0.45,
0.12)
(42) 0.01 (-0.27,
0.31)

(50) -0.28 (-0.54,
0.03)
(44) 0.02 (-0.30,
0.34)

(27) -0.02 (-0.43,
0.40)
(69) -0.08 (-0.33,
0.17)

(25) -0.36 (-0.66,
-0.09)
(67) 0.03 (-0.20,
0.24)

(27) 0.09 (-0.27,
0.46)
(71) -0.08 (-0.29,
0.16)

(26) -0.36 (-0.61,
-0.12)
(67) 0.07 (-0.16,
0.31)

(25) 0.01 (-0.38,
0.42)
(69) -0.03 (-0.28,
0.22)

(27) -0.13 (-0.45,
0.24)
(69) -0.04 (-0.28,
0.19)

(22) -0.01 (-0.46,
0.42)
(69) -0.10 (-0.32,
0.12)

(24) -0.41 (-0.72, 0.10)*
(70) -0.04 (-0.30,
0.25)

(45) 0.09 (-0.22,
0.38)
(49) -0.23 (-0.46,
0.06)

(44) 0.03 (-0.21,
0.27)
(46) -0.17 (-0.42,
0.09)

(47) -0.14 (-0.39,
0.12)
(49) -0.02 (-0.33,
0.25)

(44) -0.01 (-0.27,
0.28)
(47) -0.15 (-0.42,
0.10)

(44) -0.08 (-0.38,
0.23)
(48) -0.02 (-0.33,
0.27)

(46) -0.18 (-0.46,
0.13)
(48) -0.01 (-0.22,
0.22)

(43) -0.09 (-0.41,
0.23)
(46) 0.04 (-0.15,
0.25)

(46) 0.04 (-0.30,
0.39)
(46) -0.37 (-0.64, 0.07)*

(59) 0.06 (-0.24,
0.35)
(36) -0.22 (-0.54,
0.11)

(56) -0.05 (-0.25,
0.13)
(35) -0.12 (-0.46,
0.25)

(60) 0.04 (-0.21,
0.26)
(37) -0.09 (-0.40,
0.26)

(57) -0.01 (-0.24,
0.23)
(35) -0.07 (-0.38,
0.27)

(56) 0.03 (-0.23,
0.28)
(37) -0.14 (-0.47,
0.24)

(60) -0.03 (-0.26,
0.21)
(35) -0.04 (-0.38,
0.30)

(55) -0.17 (-0.42,
0.10)
(35) -0.08 (-0.39,
0.21)

(57) -0.03 (-0.32,
0.26)
(36) -0.30 (-0.59,
0.06)

(39) 0.02 (-0.26,
0.30)
(56) -0.10 (-0.40,
0.19)

(37) -0.17 (-0.40,
0.05)
(54) -0.05 (-0.32,
0.23)

(40) 0.04 (-0.29,
0.32)
(57) -0.06 (-0.30,
0.20)

(38) -0.21 (-0.49,
0.04)
(54) 0.08 (-0.18,
0.34)

(38) -0.04 (-0.33,
0.30)
(55) -0.03 (-0.33,
0.24)

(40) -0.07 (-0.36,
0.23)
(55) 0.01 (-0.27,
0.27)

(37) -0.03 (-0.34,
0.29)
(53) -0.18 (-0.42,
0.09)

(38) -0.10 (-0.48,
0.25)
(55) -0.16 (-0.41,
0.14)

(51) 0.02 (-0.28,
0.34)
(44) -0.12 (-0.41,
0.15)

(49) -0.09 (-0.33,
0.14)
(42) -0.07 (-0.35,
0.22)

(52) 0.06 (-0.21,
0.30)
(45) -0.10 (-0.38,
0.22)

(49) -0.02 (-0.29,
0.25)
(43) -0.05 (-0.35,
0.24)

(48) 0.07 (-0.22,
0.35)
(45) -0.15 (-0.45,
0.16)

(52) 0.02 (-0.23,
0.24)
(43) -0.09 (-0.38,
0.24)

(47) -0.13 (-0.42,
0.18)
(43) -0.12 (-0.37,
0.18)

(49) -0.06 (-0.40,
0.26)
(44) -0.21 (-0.51,
0.12)
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Bolded items indicate a significant correlation and/or one value exceeding the confidence intervals of its categorical counterpart. Grayed out regions represent excluded variables.
* = Correlation significant at the p<0.05 level
** = Correlation significant at the p<0.01 level
^ = partial moderation (interaction term retained with other variables)
^^ = full moderation (only interaction is retained)

43

Table 5 – Correlations of biomarkers with pain interference in the presence of moderators

Full sample (R (p))
Sex
Female
Male

Region of Injury
Spinal
Peripheral

BMI
≤25.09
>25.09

Employment Prior
Employed for pay
Not employed for pay

Return-To-Work Status
Full RTW
Partial or no RTW

Post-Secondary
Education
No post-secondary ed.
Post-secondary ed.
Household Income
<$80k
≥$80k

TNFα (96)

IL-10 (92)

BDNF (98)

IL-1β (93)

Cortisol (94)

TGFβ (96)

CRP (91)

IL-6 (94)

0.06 (0.56)

-0.04 (0.69)

-0.02 (0.88)

-0.00 (0.97)

-0.10 (0.33)

-0.05 (0.66)

-0.19 (0.07)

0.08 (0.47)

(56) 0.08 (-0.19,
0.33)
(39) 0.04 (-0.24,
0.31)

(53) -0.08 (-0.31,
0.15)
(38) 0.01 (-0.29,
0.27)

(58) 0.01 (-0.24,
0.26)
(39) -0.07 (-0.36,
0.24)

(53) 0.02 (-0.25,
0.31)
(39) -0.05 (-0.33,
0.23)

(57) -0.17 (-0.40,
0.09)
(36) -0.02 (-0.43,
0.31)

(57) -0.09 (-0.32,
0.15)
(38) -0.01 (-0.31,
0.36)

(54) -0.13 (-0.38,
0.15)
(36) -0.25 (-0.51,
0.07)

(56) 0.09 (-0.19,
0.38)
(37) 0.057 (0.25, 0.38)

(23) 0.38 (-0.18,
0.72)
(73) 0.01 (-0.20,
0.23)

(21) -0.25 (-0.67,
0.18)
(71) -0.02 (-0.21,
0.18)

(23) 0.32 (-0.20,
0.72)
(75) -0.09 (-0.28,
0.10)

(20) 0.32 (-0.16,
0.67)
(73) -0.07 (-0.27,
0.14)

(21) -0.52 (-0.80, 0.09)*^^
(73) 0.01 (-0.19,
0.25)

(23) 0.38 (-0.07,
0.79)^^
(73) -0.15 (-0.34,
0.06)

(20) 0.44 (-0.01,
0.81)
(71) -0.35 (-0.54, 0.14)**^^

(21) 0.25 (-0.14,
0.70)
(73) 0.04 (-0.19,
0.28)

(48) -0.05 (0.34, 0.27)
(39) 0.15 (-0.11,
0.38)

(41) -0.02 (-0.28,
0.25)
(46) -0.05 (-0.31,
0.24)

(43) -0.08 (-0.32,
0.17)
(50) 0.09 (-0.17,
0.35)

(42) -0.19 (-0.47,
0.07)
(47) 0.19 (-0.13,
0.45)

(41) -0.32 (-0.55, 0.08)*
(48) 0.03 (-0.28,
0.34)

(42) -0.12 (-0.38,
0.17)
(50) -0.01 (-0.31,
0.25)

(41) -0.23 (-0.50,
0.08)
(45) -0.15 (-0.39,
0.14)

(41) -0.03 (-0.37,
0.32)
(48) 0.25 (-0.03,
0.48)

(70) 0.04 (-0.18,
0.28)
(24) 0.02 (-0.38,
0.41)

(69) 0.00 (-0.19,
0.20)
(22) -0.11 (-0.52,
0.38)

(72) -0.10 (-0.29,
0.11)
(24) 0.10 (-0.39,
0.52)

(68) 0.06 (-0.16,
0.28)
(23) -0.39 (-0.71,
0.03)

(69) 0.00 (-0.23,
0.23)
(23) -0.25 (-0.67,
0.17)

(70) -0.02 (-0.23,
0.19)
(24) -0.19 (-0.57,
0.20)

(68) -0.13 (-0.33,
0.10)
(22) -0.31 (-0.66,
0.02)

(69) 0.02 (-0.19,
0.25)
(23) 0.18 (-0.25,
0.60)

(52) -0.01 (0.26, 0.26)
(37) 0.14 (-0.19,
0.47)

(50) -0.15 (-0.42,
0.10)
(35) 0.05 (-0.22,
0.28)

(53) -0.05 (-0.28,
0.22)
(38) -0.02 (-0.32,
0.33)

(50) -0.04 (-0.35,
0.27)
(36) 0.07 (-0.23,
0.35)

(53) 0.04 (-0.22,
0.27)
(34) -0.26 (-0.57,
0.15)

(51) 0.14 (-0.11,
0.38)
(38) -0.24 (-0.47,
0.01)

(52) -0.18 (-0.38,
0.07)
(33) -0.22 (-0.54,
0.16)

(53) -0.07 (-0.34,
0.21)
(34) 0.16 (-0.13,
0.45)

(25) -0.07 (0.47, 0.37)
(71) 0.12 (-0.10,
0.32)

(24) -0.29 (-0.61,
0.10)
(68) 0.05 (-0.16,
0.25)

(24) 0.01 (-0.29,
0.36)
(74) -0.02 (-0.25,
0.20)

(25) 0.14 (-0.31,
0.60)
(68) -0.07 (-0.29,
0.14)

(22) -0.04 (-0.41,
0.40)
(72) -0.14 (-0.38,
0.10)

(24) -0.08 (-0.44,
0.32)
(72) -0.03 (-0.26,
0.19)

(21) -0.51 (-0.73, 0.18)*
(70) -0.09 (-0.31,
0.13)

(22) 0.06 (-0.34,
0.50)
(72) 0.09 (-0.15,
0.33)

(46) -0.13 (0.44, 0.17)
(47) 0.23 (-0.01,
0.46)

(45) -0.09 (-0.32,
0.19)
(45) -0.00 (-0.33,
0.26)

(48) -0.06 (-0.32,
0.22)
(47) -0.07 (-0.30,
0.19)

(45) -0.18 (-0.45,
0.11)
(45) 0.15 (-0.14,
0.40)

(45) -0.16 (-0.43,
0.15)
(46) 0.08 (-0.18,
0.32)

(47) -0.04 (-0.31,
0.22)
(46) -0.12 (-0.37,
0.15)

(43) -0.27 (-0.53,
0.05)
(46) -0.01 (-0.26,
0.25)

(45) -0.04 (-0.34,
0.27)
(46) 0.12 (-0.17,
0.45)

Pre-Existing
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Psychopathology
Yes
No
Pre-Existing Pain
Yes
No

Peri-Traumatic Fear
No
Yes

Depression
Likely depressed
Not likely depressed

Peri-traumatic Stress
Low stress (<2)
High stress (2 or more)

Any ACE
At least one
None

Any ACE personal
At least one
None

Any ACE other
At least one
None

(26) -0.06 (0.44, 0.31)
(69) 0.10 (-0.15,
0.35)

(25) -0.36 (-0.67,
-0.04)
(66) 0.07 (-0.15,
0.27)

(26) -0.11 (-0.43,
0.22)
(71) 0.01 (-0.21,
0.24)

(25) -0.37 (-0.67,
0.05)
(67) 0.07 (-0.16,
0.28)

(25) 0.02 (-0.31,
0.31)
(68) -0.15 (-0.38,
0.09)

(26) -0.31 (-0.62,
0.11)
(69) 0.06 (-0.16,
0.27)

(23) -0.26 (-0.63,
0.09)
(67) -0.16 (-0.36,
0.09)

(23) -0.19 (-0.64,
0.31)
(70) 0.15 (-0.08,
0.37)

(17) 0.24 (-0.16,
0.71)
(76) 0.06 (-0.14,
0.26)

(16) 0.32 (-0.10,
0.66)
(73) -0.12 (-0.35,
0.09)

(17) 0.12 (-0.34,
0.62)
(78) -0.10 (-0.28,
0.10)

(17) 0.49 (-0.00,
0.86)*^
(75) -0.13 (-0.36,
0.09)

(17) -0.20 (-0.67,
0.19)
(74) -0.02 (-0.25,
0.20)

(16) 0.13 (-0.33,
0.70)
(77) -0.10 (-0.30,
0.12)

(14) -0.30 (-0.65,
0.21)
(75) -0.17 (-0.38,
0.07)

(15) 0.42 (-0.24,
0.81)
(77) 0.02 (-0.21,
0.26)

(50) -0.08 (0.33, 0.19)
(46) 0.19 (-0.08,
0.47)

(50) -0.21 (-0.46,
0.04)
(42) 0.16 (-0.09,
0.41)

(52) -0.03 (-0.25,
0.22)
(46) 0.04 (-0.28,
0.34)

(49) -0.23 (-0.48,
0.05)
(44) 0.29 (0.04,
0.51)^

(51) -0.04 (-0.33,
0.23)
(43) -0.19 (-0.51,
0.14)

(50) -0.02 (-0.27,
0.22)
(46) -0.04 (-0.33,
0.26)

(49) -0.26 (-0.47,
0.00)
(42) -0.12 (-0.42,
0.16)

(50) -0.20 (-0.45,
0.09)
(44) 0.28 (0.02,
0.52)^

(27) -0.07 (0.44, 0.36)
(69) 0.11 (-0.09,
0.32)

(25) -0.24 (-0.60,
0.15)
(67) -0.03 (-0.25,
0.19)

(27) 0.22 (-0.18,
0.55)
(71) -0.09 (-0.30,
0.10)

(26) -0.15 (-0.48,
0.21)
(67) 0.00 (-0.24,
0.23)

(25) -0.21 (-0.57,
0.13)
(69) -0.02 (-0.25,
0.20)

(27) 0.01 (-0.33,
0.37)
(69) -0.11 (-0.32,
0.14)

(22) -0.11 (-0.56,
0.32)
(69) -0.18 (-0.37,
0.02)

(24) -0.21 (-0.55,
0.19)
(70) 0.15 (-0.09,
0.38)

(45) 0.03 (-0.27,
0.32)
(49) 0.07 (-0.18,
0.34)

(44) -0.01 (-0.30,
0.27)
(46) -0.06 (-0.28,
0.15)

(47) -0.24 (-0.43,
-0.01)
(49) 0.15 (-0.11,
0.41)

(44) -0.01 (-0.31,
0.28)
(47) -0.05 (-0.33,
0.25)

(44) -0.14 (-0.41,
0.16)
(48) -0.08 (-0.35,
0.18)

(46) -0.31 (-0.54, 0.03)*^
(48) 0.13 (-0.12,
0.39)

(43) -0.17 (-0.42,
0.11)
(46) -0.08 (-0.35,
0.22)

(46) 0.14 (-0.16,
0.47)
(46) -0.02 (-0.28,
0.28)

(59) 0.00 (-0.26,
0.25)
(36) 0.18 (-0.13,
0.44)

(56) -0.11 (-0.33,
0.12)
(35) 0.050 (0.29, 0.38)

(60) 0.02 (-0.22,
0.26)
(37) -0.02 (-0.31,
0.29)

(57) -0.06 (-0.30,
0.17)
(35) 0.10 (-0.23,
0.45)

(56) -0.02 (-0.28,
0.24)
(37) -0.21 (-0.48,
0.09)

(60) -0.02 (-0.26,
0.24)
(35) -0.07 (-0.42,
0.28)

(55) -0.27 (-0.47, 0.04)*
(35) -0.12 (-0.42,
0.22)

(57) 0.07 (-0.21,
0.35)
(36) 0.10 (-0.22,
0.43)

(39) -0.04 (0.33, 0.25)
(56) 0.16 (-0.08,
0.38)

(37) -0.15 (-0.42,
0.12)
(54) 0.01 (-0.25,
0.24)

(40) -0.02 (-0.31,
0.25)
(57) 0.00 (-0.26,
0.28)

(38) -0.13 (-0.40,
0.17)
(54) 0.08 (-0.19,
0.35)

(38) -0.20 (-0.50,
0.13)
(55) -0.04 (-0.31,
0.23)

(40) -0.01 (-0.26,
0.26)
(55) -0.06 (-0.34,
0.24)

(37) -0.19 (-0.44,
0.09)
(53) -0.22 (-0.45,
0.03)

(38) -0.02 (-0.34,
0.28)
(55) 0.14 (-0.12,
0.44)

(51) -0.04 (0.32, 0.26)
(44) 0.17 (-0.06,
0.39)

(49) -0.15 (-0.42,
0.11)
(42) 0.07 (-0.20,
0.33)

(52) 0.02 (-0.23,
0.31)
(45) -0.03 (-0.28,
0.24)

(49) -0.11 (-0.37,
0.15)
(43) 0.09 (-0.21,
0.37)

(48) 0.06 (-0.26,
0.34)
(45) -0.25 (-0.49,
0.04)

(52) 0.00 (-0.23,
0.26)
(43) -0.09 (-0.37,
0.22)

(47) -0.28 (-0.50, 0.04)
(43) -0.14 (-0.40,
0.13)

(49) 0.02 (-0.28,
0.33)
(44) 0.11 (-0.19,
0.41)
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Bolded items indicate a significant correlation and/or one value exceeding the confidence intervals of its categorical counterpart. Grayed out regions represent excluded variables.
* = Correlation significant at the p<0.05 level
** = Correlation significant at the p<0.01 level
^ = partial moderation (interaction term retained with other variables)
^^ = full moderation (only interaction is retained)
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Table 6 – Significant Moderators identified for Hierarchical multiple Regression
Analyses
A – Pain Severity
β (95%CI)

R2 (Δr2)

F change (p)

TNF-α

-1.94 (-3.72, -0.16)

0.01 (0.01)

0.42 (0.52)

Employment Prior

-0.86 (-1.75, 0.04)

0.04 (0.04)

3.63 (0.06)

TNF-α x Employment
Prior

1.37 (0.07, 2.67)

0.09 (0.04)

4.39 (0.04)

TGF-β

-0.06 (-0.09, -0.02)

0.01 (0.01)

0.56 (0.46)

Pre-Existing
Psychopathology

0.05 (-0.81, 0.90)

0.01 (0.00)

0.14 (0.71)

TGF-β x Pre-existing
Psychopathology

0.03 (0.01, 0.05)

0.09 (0.08)

7.95 (<0.01)

CRP

0.06 (0.00, 0.11)

0.01 (0.01)

0.56 (0.46)

Sex

0.46 (-0.36, 1.27)

0.03 (0.02)

1.68 (0.20)

CRP x Sex

-0.04 (-0.07, -0.01)

0.09 (0.06)

5.98 (0.02)

β (95%CI)

R2 (Δr2)

F change (p)

IL-1β

59.96 (13.65, 106.27)

0.00 (0.00)

0.01 (0.94)

Pre-Existing Pain

-9.92 (-18.32, -1.52)

0.07 (0.07)

6.88 (0.01)

IL-1β x Pre-Existing Pain

-32.03 (-56.07, -8.00)

0.14 (0.07)

7.01 (0.01)

IL-1β

29.79 (6.25, 53.33)

0.00 (0.00)

0.00 (0.97)

Peri-Traumatic Fear

-9.18 (-15.83, -2.53)

0.07 (0.07)

6.45 (0.01)

IL-1β x Peri-Traumatic
Fear

-18.94 (-33.58, -4.29)

0.13 (0.06)

6.60 (0.01)

Cortisol

-0.18 (-0.35, -0.02)

0.01 (0.01)

0.95 (0.33)

Region of Injury

4.56 (-3.67, 12.78)

0.02 (0.01)

0.51 (0.48)

Cortisol x Region of

0.09 (0.00, 0.18)

0.06 (0.05)

4.30 (0.04)

B – Pain Interference
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Injury
TGF-β

0.41 (-0.01, 0.82)

0.00 (0.00)

0.19 (0.66)

Region of Injury

2.51 (-5.28, 10.30)

0.01 (0.01)

1.08 (0.30)

TGF-β x Region of Injury

-0.23 (-0.45, -0.01)

0.06 (0.05)

4.37 (0.04)

TGF-β

-0.28 (-0.53, -0.04)

0.00 (0.00)

0.14 (0.71)

Peri-Traumatic Stress

10.58 (4.13, 17.04)

0.09 (0.09)

8.91 (<0.01)

TGF-β x Peri-Traumatic
Stress

0.17 (0.01, 0.32)

0.13 (0.04)

4.56 (0.04)

CRP

0.66 (0.17, 1.15)

0.04 (0.04)

3.38 (0.07)

Region of Injury

5.74 (-1.70, 13.19)

0.06 (0.02)

1.96 (0.17)

CRP x Region of Injury

-0.44 (-0.71, -0.17)

0.16 (0.10)

10.28 (<0.01)

IL-6

4.38 (0.71, 8.05)

0.01 (0.01)

0.54 (0.47)

Peri-Traumatic Fear

-8.14 (-14.56, -1.72)

0.06 (0.06)

5.30 (0.02)

IL-6 x Peri-Traumatic
Fear

-2.84 (-5.26, -0.42)

0.11 (0.05)

5.45 (0.02)
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Figure 1 – Graphical Representation of Pain Severity Moderators
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Figure 2 – Graphical Representation of Pain Interference Moderators
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Chapter 3

3

Exploring recovery trajectories and predicting outcomes
of acute musculoskeletal trauma using latent growth
curve analysis

3.1 Introduction
Pain following musculoskeletal trauma is a complex phenomenon. While early models
conceptualized pain as a direct result of the magnitude of tissue damage, newer models
have re-conceptualized it as a highly subjective experience influenced by interactions of
biology, psychology and social influences 1. The experience of pain is a nearly universal
phenomenon, and is widely recognized as essential for survival learning in most
organisms including humans 2. However, its inconsistent relationship to key
physiological mechanisms 3 has made its regulation difficult. Unresolved pain can
disrupt multiple aspects of life 4 and without proper control, pain has been considered its
own pathological condition 5. The incidence and prevalence of chronic pain is estimated
to be nearly 20% of adults in Canada 6 and the United States 7 with staggering economic
and social burden 8. With pain being such a complex and integrated experience, health
care providers can struggle to navigate the various interactions that lead to the
development of chronic pain.

Many scholars in the field have argued that better mechanism-based prognostic models
are needed to identify key intervention targets in the acute stage of injury and pain to
prevent poor outcomes 9,10. There has yet to be consistent evidence that any intervention
strategy effectively prevents the transition to chronicity rendering the field no further
ahead than it has been over the past several decades. Additionally, the use of opioids in
acute pain management or as a long-term solution has been heavily scrutinized in recent
years, driven largely by findings that prolonged administration (> 3 months) significantly
increases the likelihood of physical or psychological dependence 11. This general lack of
effectiveness in preventing chronic or persistent pain is driven at least in part by poor
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understanding of the mechanisms that explain the acute-to-chronic or acute-to-recovery
transitions 12.

Pain prognosis as a field of study has evolved considerably over the past two decades,
with emphasis added during the mid-1990s from groups exploring acute whiplashassociated disorder 13 and acute low back pain 14. However, considerable challenges
persist today, including the nature of the outcomes to be predicted and the multitude of
confounding influences that very likely exist when creating prognostic models 15.
Traditionally, pain intensity (or severity) has been the most common outcome predicted
in prognostic research following musculoskeletal trauma 16 and is not coincidentally one
of the most reliable predictors of a poor outcome 17. More recently however,
psychological and physical function outcomes have been included in these models. For
example, Sterling and colleagues conducted latent growth curve modeling in a sample of
155 people with acute (<1 month) whiplash and found that a 3-class model (mild,
moderate, severe) best described the trajectory of outcomes for both physical (Neck
Disability Index 18) and emotional (Post-traumatic Stress Diagnosis Scale 19) functioning.
Panken and colleagues 20 similarly conducted latent growth curve analysis to again
identify 3 emergent trajectories that best described the progress of pain intensity in 622
participants with low back pain of median 5.8 weeks duration (2 to 780 weeks). The 3class trajectories model appears to be showing consistency in this literature, though
outstanding questions persist including the translation of these findings to injuries
affecting other parts of the body, and other relevant physical and psychological outcomes.
That is, how consistent are these models in more heterogeneous samples when different
outcomes are used? A better understanding of recovery trajectories will facilitate
prognostic assessment of patients and help to direct healthcare resources to those who
would benefit most while preventing overtreatment of those who are likely to recover
quickly.

Therefore, the purpose of this study was to investigate the recovery trajectories following
non-catastrophic MSK trauma in a general population which includes both axial and
peripheral trauma. This was conceptualized as a first step towards a body region-
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agnostic approach to prognostic phenotyping of people with acute, non-catastrophic MSK
trauma.

3.2 Methods
3.2.1

Participant recruitment

Data for this analysis were drawn from two longitudinal cohort studies, one in London
Ontario, Canada (SYMBIOME, Systematic Merging of Biology, Mental Health and
Environment, clinicaltrials.gov ID no. NCT02711085) and one in Chicago Illinois,
United States (ID no. NCT02157038). Eligible participants were identified by emergency
or acute-care nursing or medical clinicians, all within 4 weeks of musculoskeletal (MSK)
trauma. All participants were 18 to 65 years, had to have suffered a non-catastrophic
MSK injury that did not require inpatient admission or surgical correction, and could
speak and understand conversational (at least grade 8) English. Exclusion criteria were
those with one or more prior motor vehicle collisions (Chicago cohort only), any nervous
system or major systemic disorders that would be expected to otherwise impair recovery
independently of the trauma, and any metabolic systems disorders (Chicago cohort only).
Co-treatment or other chronic comorbidities were captured as part of the intake and
follow-up packages. The London cohort included participants with non-catastrophic
musculoskeletal (MSK) injury affecting any body region, while the Chicago cohort
included only those with whiplash-associated symptoms about the neck arising from
motor vehicle collisions. After being medically cleared and discharged, interested
participants gave permission for a member of the research team to describe the study,
answer questions, and consent to enroll prior to leaving the hospital. Participants were
provided a package of self-report questionnaires to be completed within 24 hours of
discharge. Biomarker data were also collected from participants though these differed
considerably between the two cohorts so could not be combined and are not being
described here. Follow-up in the two cohorts occurred within 1 month from inception,
and again 3 and 12 months after injury.
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3.2.2

Psychometric variables and metadata

The questionnaires differed slightly between the two cohorts, though the constructs being
captured were similar enough to allow meaningful pooling. Both studies captured
demographic and social data including age, sex, body mass index (BMI, kg/m2), work
status, medicolegal status, and significant comorbidities (e.g. depression or other mood
disorders, existing pain conditions). The primary outcome for defining recovery
trajectory was pain-related functional interference as measured by the Interference
subscale of the Brief Pain Inventory (BPI 21, London cohort) or the Neck Disability Index
(NDI 18, Chicago cohort). The BPI is one of the most widely used pain interference scales
globally 22 and has considerable evidence of validity across many clinical populations
including musculoskeletal pain 23. The NDI is one of the most widely-used regionspecific scales for capture of neck-related disability specifically and is more relevant to
that population. The two tools share several items including work ability, sleep, and
recreation, but the NDI excludes items irrelevant to those with neck pain like walking
interference. Both the NDI and the BPI have demonstrated acceptable reliability, validity
and responsiveness for capturing interference 18,21,23-26. Both can easily be converted into
a percentage score of the total scale range (0% = no interference, 100% = complete
interference), allowing meaningful combination of the two databases. The NDI shows a
moderate (r = 0.58) 27 to strong (r = 0.71) 28 correlation with the NPRS dependent on the
time-frame explored. The NDI was also shown to have a strong correlation to the visual
analogue scale (r = 0.64) 29. Our database demonstrated a similar correlation between the
BPI interference subscale and the NPRS (r = 0.67).

Pain severity as a secondary outcome was captured from all participants at each data
collection period using a standard 0-10 Numeric Pain Rating Scale (NPRS) in both
cohorts.

Intervention between follow-up periods, if any, occurred at the discretion of the
participant and healthcare providers. Type of intervention was captured (e.g. physical
therapy, pharmaceuticals, massage therapy, work hardening) though the balance of
evidence available in the field does not support the superiority of any treatment modality
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over others, including type of intervention, frequency, dosage or intensity, when
compared to simple advice and education 30-33. As such, intervention type was captured in
general terms only. Ethics approval was obtained by the respective research ethics boards
prior to recruiting participants into the study. Participants were reimbursed up to the
equivalent of $240 Canadian dollars for expenses and time incurred during participation
across all follow-up periods.

3.3 Analysis
3.3.1

Pre-Analysis

Participant metadata (age, sex, BMI, medicolegal status, work status) and baseline scores
on each of the outcomes were evaluated descriptively (frequencies, means, ranges). The
primary (% pain interference) and secondary (pain severity) outcomes were first explored
for missing data and normality. Region of injury was coded according to the primary area
of symptoms; presence of any head, neck or back injuries (regardless of additional
peripheral injuries) were classified as “axial” while those affecting the upper or lower
extremities (shoulder, elbow, wrist, hip, knee, ankle) were classed as “peripheral”.
Where necessary, data were square-root transformed in order to reduce the skewness of
the distribution to within acceptable limits.

3.3.2

Latent Growth Curve Analysis

Latent growth curve analysis (LGCA) was conducted on the square-root transformed data
to identify the number of trajectories definable by each of the 2 primary outcomes
following the steps of DiStefano and Kamphaus 34 using the Growth Mixture Modeling
(GMM) function in MPlus v6.12 software (Muthen & Muthen, Los Angeles USA). For
each, a series of models were constructed, starting with a single trajectory (termed
‘class’) and increasing until model fit no longer improved, the model could no longer be
mathematically defined, one of the latent classes possessed fewer than 10% of
participants, or the class structure did not make clinical sense. The fit indicators of
interest were the Akaike Information Criterion (AIC) 35-37, the Bayesian Information
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Criterion (BIC) 35-37, entropy 36, and the adjusted Lo-Mendell-Rubin likelihood ratio test
(LMR-LRT)35,37. While no set criteria exist for deeming model fit acceptable 37, the
cluster solution that provides the lowest AIC and BIC and the highest entropy value
(ideally >0.80) that also conforms to theory is generally considered optimal 38. An
additional statistical analysis was conducted using the k-means approach, where the LoMendell-Rubin Adjusted Likelihood Ratio Test (LMR-LRT) is used to statistically
compare the fit of the k cluster solution (e.g. 3) with that of the k-1 class solution (e.g. 2).
When fit no longer statistically improves (p>0.05) with the addition of a new class, the
solution with the smaller number of classes is generally accepted for reasons of
parsimony 37,39. Both linear and quadratic (non-linear) models were tested.
After the optimal model solution was identified, each participant received an assignment
to the most likely trajectory based on posterior probabilities from the modeling
procedure. Owing to >20% missing data across all time points, a validation step was
undertaken to improve confidence in the model solution. A repeated measures ANOVA
with 4 levels of repeated variable (time: 0, 1, 3, and 12 months) and trajectory class as the
between group variable was conducted on the raw interference or NPRS scores to ensure
main effects of group and time were statistically significant and meaningful. Significant
main effects were further explored using Tukey’s post-hoc test or t tests with Bonferroni
correction.

Prior research has suggested that that axial injuries (i.e. head, neck, and back) have more
than twice the functional interference than injuries in other areas 40. As such, a planned
disaggregated sub-analysis was also conducted where the trajectories were explored in
the axial and peripheral groups separately. Consistencies in trajectory shapes were
expected, but proportions within each trajectory were hypothesized to be different, with
proportionately greater representation of the axial traumas in the more severe pain
groups.

As exploration of quadratic functions with 12-month outcomes was a planned analysis,
only those participants with at least 3- or 12-month outcome data were included for each
analysis. If participants were missing data for both 3 and 12 months, they were excluded
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from outcome analysis. In those with a single missing value, data were estimated using
maximum likelihood estimation based on all the available data in order to generate an
acceptable class solution for recovery. This is an acceptable method for dealing with
missing values which makes use of all available data to estimate an appropriate model
that can be used to describe the entire sample 41,42. As an additional measure of
trustworthiness in model-estimated values, observed 12-month values for both pain
severity and interference were compared against the MPlus-generated estimated values
via t-test to ensure that no significant differences existed.

3.3.3

Sample size estimation

Previous studies investigating pain recovery trajectories using latent growth curve
modeling and ANOVA-based approaches have identified distinct classes with a medium
effect size 43. A power analysis was conducted using G*Power v3.1 44 indicating that a
total sample of 189 participants would be required to detect moderate effects (ηp2 = 0.03)
with β = 80% using RM ANOVA between means with α = 0.05.

3.4 Results
3.4.1

Participant characteristics

A total of 231 participants were recruited within 28 days (4 weeks) of non-catastrophic
MSK trauma. Of those, 134 were from the London Ontario sample and 97 from the
Chicago Illinois sample. The sample was 54.9% male, mean age of 39.7 years, average
BMI of 26.1kg/m2, and the modal cause of injury when the two databases were combined
was motor vehicle collision (50.5% of responses). Table 7 presents the remaining
participant characteristics including baseline mean values on each of the 4 primary
outcomes. Participants described a mix of axial (59.9%) or peripheral (40.1%) injuries.
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3.4.2

Latent Growth Curve Analysis

The dataset for the base model included all 241 participants (axial and peripheral
combined). Table 8 presents the results of the 1, 2, 3, and 4-class models, for both the
linear and the quadratic functions. In reviewing the fit indicators and clinical utility, the
3-class quadratic model for square-root percent interference was deemed optimal (AIC =
2911.63, BIC = 2973.59, Entropy = 0.68, LMR-LRT = 46.12, p<0.01 vs. the 2-class
model). The 3 trajectories were labeled according to the intercepts, slopes, and quadratic
functions of the curves: Curve 1 = Rapid recovery (lowest intercept, full or near full
recovery by 3 months, 34.9% of the sample); Curve 2 = Delayed recovery (higher
intercept, near linear recovery through to 12 months, 19.2% of the sample); Curve 3 =
Little or no recovery (higher intercept, slight downward curve at later follow-up but
persistently high interference scores, 45.9% of the sample).

Fit indicators for the pain severity outcome were optimal for a 2-trajectory quadratic
model (AIC = 2935.51, BIC = 2983.58, Entropy = 0.79, LMR-LRT = 81.03, p<0.01).
These were labeled: Curve 1 = Rapid recovery (lower intercept, recovery by 3 months
with a flattened curve thereafter, 83.4% of the sample); and Curve 2 = Minimal or no
recovery (higher intercept, persistent higher pain severity ratings at 12 months despite
some improvement, 16.6% of the sample). While the inclusion of the quadratic term led
to more meaningful model results for both the interference and pain outcomes, we had to
constrain variance in that term to zero to achieve adequate convergence (essentially
forcing each participant within a trajectory to have the same non-linear trajectory).
Figures 3 (Percent Interference) and 4 (Pain Severity) present the trajectories graphically.
Planned disaggregated analysis of axial vs peripheral injury yielded qualitatively similar
trajectories with slight differences in proportions; where the axial injuries contained a
higher proportion of Minimal or No Recovery and peripheral injuries contained a higher
proportion of Rapid Recovery in accordance with our a priori hypotheses. The
similarities in these trajectories lend support to maintaining a combined injury model that
incorporates both axial and peripheral injury.
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3.4.3

Validation

An RM ANOVA was performed with time as the repeated factor and ‘class assignment’
as the between-subjects factor. The results demonstrate a significant main effect of group
(F (2,231) = 517.14, p<0.01) and time (F (1,231) = 3779.41, p<0.01) for pain interference
in the expected directions. The interaction term between group and time was also
significant (F (2,231) = 518.47, p<0.01). Mean percent interference was significantly
lower in Curve 1 (rapid recovery) than the other two, and was significantly higher in the
Curve 3 (little or no recovery) than the other two. Tukey’s post-hoc revealed that mean
interference was not different between the delayed and minimal recovery trajectories
until the 3 month follow-up, supporting the label of ‘Delayed Recovery’ (p<0.01). At 12
month follow-up, Rapid and Delayed Recovery trajectories were not significantly
different (p=0.07). The same RM ANOVA analysis was also performed for pain
severity. As a 2-class combined injury model, there was significant main effect of group
(F (1,227) = 357.93, p<0.01) and time (F (1,227) = 366.13, p<0.01). There was also a
significant interaction effect of group and time (F (1,227) = 302.68, p<0.01), with
significant differences at each time point based on independent samples t-tests with
Bonferroni correction (p<0.0125). Mean severity was significantly lower in Curve 1
(rapid recovery) than in Curve 2 (minimal/no recovery). Further, the predicted models
appeared sound even despite any missing data as there were no significant differences
between 6-month predicted and observed values (all p>0.40, Tables 10A and B).
To better describe the relationship between trajectory and actual distal outcome, we first
trichotomized the 12-month interference scores using simple thresholds informed by the
nature of the data: those scoring 0-5% interference at 12 months were considered to be
experiencing no clinically meaningful ongoing problems, those score 5-20% were
considered to be experiencing mild ongoing problems, and those scoring over 20% were
considered persistent and clinically relevant problems, in general accordance with widely
accepted thresholds for NDI scores 45 (Table 10A and 10B). Owing to missing data by 12
months, 184 complete datasets (76.3% of baseline) were available for this analysis. A 3 x
3 cross-tabulation was established, shown in Table 10. No participants in the Rapid or
Delayed interference recovery trajectories rated >20% interference at 12 months, though
a combined 9 participants rated mild persistent problems. Similarly, only 1 participant
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classed in the Minimal or No Recovery trajectory rated <5% interference at 12 months,
while 56 (59.6% of those in that trajectory) rated 5-20% interference. These proportions
indicated a clear distinction between the Rapid and Minimal or No Recovery trajectories
in accordance with the labels given them, but some ambiguity in the middle trajectory
and mild interference outcome. With regard to pain severity, all of the participants in the
Minimal or No Recovery trajectory reported persisting pain of at least 4/10 severity at 12
months. In the Rapid recovery trajectory, 74 participants (51.0% of the class) indicated
having no pain (0 out of 10) at 12 months, however 71 participants (49.0%) indicated
some degree of pain severity still present at 12 months (ranging from 1 to 3 out of 10).

3.5 Discussion
This study provides evidence for the general decrease in disability and pain intensity over
the course of 12 months in a mixed adult population following non-catastrophic axial or
peripheral trauma. These dimensions appear to stabilize at approximately 3 months postinjury. Our results also suggest that classification of recovery following non-catastrophic
injury is determined by both the intercept (baseline symptoms) and slope (relative rate of
symptom decline). This is in keeping with known associations between pain perception
and the severity of future pain in both pediatric 46 and adult populations 47-49.
In accordance with previous research by Sterling and colleagues 12, 50, we have identified
3 distinct classes of recovery for axial injuries in disability/pain interference. In addition,
we have also demonstrated that these same recovery classes may also include perceived
disability in peripheral injuries as our 3-class model was a mixed injury group, and
disaggregated analyses showed qualitatively similar trajectories exist in both groups.
With respect to pain interference, the majority of participants seemed to belong to the
minimal/no recovery class (45.9%), however, the majority of our sample consisted of
axial injuries (52.7% neck injuries and 9.1% lower back). This may have resulted in a
higher number of participants experiencing persistent interference from their pain. This
is in keeping with prior research that suggests a greater level of disability among axial
injuries 40. Pagé et al have also identified 3 predictive trajectories of pain intensity and
disability in a study of over 1800 participants with mixed conditions enrolled in the
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Quebec Pain Registry 51. That registry however contains only those who have already
been diagnosed with chronic pain and trajectories were based on recovery while in a
multidisciplinary pain program. Studies investigating the trajectories of post-operative
pain have also identified 3 distinct groupings based on initial severity of symptoms 52, 53.
Other studies investigating hip 54 and low back pain 55 recovery have identified 4- and 5class models, respectively. However, in both studies, three categories of stable symptoms
were always identified (low/mild, moderate persistent, and severe persistent); where
additional classes were reflective of those who experienced fluctuating pain over the
course of years.

Based on our data, pain severity seemed to favor a 2-class model. This differs from our
3-class model of pain interference. Although severity and interference are related, they
are still considered separate constructs of pain measurement 21. These dimensions can
present differently such that it is possible to have a high level of pain intensity with a
relatively low level of interference or disability 56. Table 1 shows that 19.2 % of our
participants scored over threshold for likely depression and 19.7% scored over threshold
for likely PTSD at entry into the study. Approximately 16.6% of participants were also
placed into the minimal or no recovery group for pain severity upon conclusion of the
study. Although no conclusions can be drawn from these observations, chronic pain is
often closely associated with a number of psychological disturbances including PTSD,
depression, and anxiety 57, 58. Whether or not these factors are linked in our study is up
for debate, but the literature suggests that there is a connection between the changes in
pain, depression, and anxiety over time. Gerrits and colleagues have investigated this
synchronicity by measuring longitudinal changes in these symptoms in more than 2000
participants 59. Over the course of 4 years, participants that had either a chronic or
incident anxiety/depression diagnosis reported significantly higher pain compared to
healthy controls. The participants who were in remission from their depression or
anxiety at follow-up reported decreased levels of pain compared to chronic cases but
were still significantly higher than healthy counterparts 59. From a psychosocial
perspective, Bonanno and colleagues investigated the trajectories of depression following
traumatic spinal cord injury over the course of 2 years 60. They identified 2 stable classes
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that emerge from the beginning with 2 additional classes that fluctuate over time. Their
results suggest that after 1 year there is a gradual trend toward the 2 stable classes 60.
Psychological comorbidity is closely tied to the overall experience of pain.
Radiofrequency neurotomy in whiplash patients has shown that general psychological
distress detected upon intake was resolved with the successful post-operative resolution
of pain symptoms 61. Similarly, disability and pain intensity can be affected to some
degree by the resolution of tissue damage; whereas PTSD and depression (relating to
emotional reactivity) may be more closely associated with pre-existing and ongoing
psychosocial factors. It has been shown in post-traumatic distress that the occurrence of
an initial traumatic event can psychologically sensitize the brain to subsequent trauma 62,
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; which may explain why those with higher symptom severity at intake, continued along

an elevated trajectory. More recently, Sterling and colleagues demonstrate a considerable
agreement between trajectories of neck disability and post-traumatic distress. They also
assert that membership in the disability and PTSD groups are determined by similar
factors 12.

As table 10A and 10B suggest, our trajectories, while achieving acceptable fit to the data,
still showed considerable inter-individual variation. Even in those who are on a rapid or
delayed recovery process, 4.86% still present with mild-moderate levels of pain
interference and 49.0% present with pain severity greater than 0 at their 6-month
outcome. Our study population consists of many different types of MSK trauma and it is
possible that this variety of traumatic injuries may be contributing to the variations in
each recovery class. It is more likely however that this variability is a product of
inherent, inter-individual differences. In a controlled environment with experimentallyinduced pain (i.e. the same noxious stimulus being applied to everyone), healthy
participants can indicate anywhere between 2 to 9 out of 10 on the visual analog scale of
pain measurement 64. These ratings were also proportional to the amount of neurological
activity recorded in the pre-frontal cortex (executive function), anterior cingulate cortex
(emotional reaction to pain, goal setting), and the primary somatosensory cortex
(incoming sensory information) 65. This suggests that the variability is not simply an
error involved with subjective reporting, but that it is indicative of actual neurological
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differences in the experience of pain 64, 65. Regardless of the mechanism of injury, the
perception of pain is highly specific to the person. Although we have demonstrated the
emergence of distinct recovery classes in pain severity and interference, the information
gleaned from these trajectories should be used with caution. As we have shown, the
recovery class alone is insufficient to capture individual variability and completely
predict 6-month outcomes. Both the pathway and the eventual outcome should be taken
into consideration when defining recovery.

A few limitations need to be taken into consideration. The data used in the analysis were
entirely generated via self-report for all constructs tested. This creates the potential to
overestimate symptom severity. However, there is correlation between self-report and
neural activity, and despite advances that have been made in pain neuroimaging, the most
reliable measurement of pain over time in healthy individuals continues to be subjective
self-report data 66. The data itself were also compiled from two separate sites, one in
Canada and one in the US, using constructs that were related but not identical. Despite
the high level of agreement between the constructs being used, the exclusive focus on
non-catastrophic neck trauma in the Chicago cohort compared to the multi-region trauma
in the London cohort will inevitably add variation within the data. The use of two
different scales for capturing pain-related interference between the two cohorts is
definitely a limitation of this study, however both the NDI and the BPI interference
subscale correlate strongly with standard measures of pain severity (NRS). From
previous work on recovery trajectories 54, 55, it is possible that additional classes do exist
and that our study lacks the adequate power to detect these smaller, more labile classes.
However, our findings are in agreement with other studies of similar design 12, 50, and
although no strict guidelines exist for adequate sample size for growth curve modeling, it
is suggested that at least 100 participants are required in order to avoid underreporting the
“correct” number of classes 67. Other classes may also represent smaller, more
statistically uncommon proportions of the population which may not be as clinically
relevant as the broader groups.

67

In conclusion, findings of previous groups of a 3-class recovery trajectory model were
replicated in our more heterogeneous sample of non-catastrophic acute MSK trauma,
though pain severity tended to favor a 2-class recovery model. Graphical depiction of
individual trajectories and crosstabulation of both recovery trajectory and 6-month
outcome suggest a general agreement between course and state of recovery, though some
symptom variability within each recovery class suggests that future researchers should
consider both the trajectory and distal outcome when conducting longitudinal research.
Recovery trajectories may help to guide prognosis and treatment but are insufficient on
their own to dictate total recovery or eventual outcomes.
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Table 7 – Participant characteristics
Sex (% male)
Cause (%)
Motor vehicle collision
Fall / Slip
Hit by person or object (not MVC)
Awkward lift or twist
Other
Body Region Injured (%)1
Neck
Shoulder
Elbow
Wrist or Hand
Lower Back
Hip
Knee
Foot or Ankle
Employment (%)
Full-Time
Part-Time
Off Work (temporary)
Not Employed for Pay
Current Work Status (%)
Full Return
Partial Return
No Return
Educational Attainment (%)
High School or Less
Community College or Trade School
University Undergraduate Degree
University Graduate Degree
Other
Household Income
≤$20,000
$21,000 - $80,000
$81,000 - $150,000
>$150,000
Pre-Existing Pain (% yes)2

54.9%
50.5%
14.2%
9.4%
8.0%
17.9%
52.7%
9.1%
3.6%
15.5%
9.1%
2.3%
8.6%
16.4%
58.8%
14.9%
2.6%
23.7%
56.6%
25.4%
18.0%
25.0%
31.9%
29.3%
12.1%
1.7%

7.1%
45.1%
36.3%
11.5%
17.1%
Continuous Variables
Variable
Mean (SD, range)
Age (years)
39.7 (13.8, 18 to 66)
2
Body Mass Index (kg/m )
26.1 (5.4, 14.4 to 51.5)
Post-Traumatic Distress (% of total score)3
19.7% (19.7%, 0 to 94)
4
Depressive Symptoms (% of total score)
19.2% (19.1%, 0 to 95)
5
Pain Interference (% of total score)
37.6% (21.0%, 0 to 96)
Pain Severity (0-10 NRS)
4.6 (2.2, 0 to 10)
1: The total proportions will exceed 100% as participants were free to choose more than one body region.
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2: Pre-existing pain was identified by reviewing medication lists for any analgesic medication and co-morbidity lists for any painrelated condition (e.g. fibromyalgia, osteoarthritis, repetitive strain injuries, neck or back pain, etc…).
3: Post-Traumatic distress was captured using two different but related tools: The PTSD Checklist, The PTS Diagnosis Scale. Results
have been reported as a percentage of total scale score.
4: Depressive symptoms were captured using the depression subscale of the HADS (HADS-D) and the PHQ-9. Results have been
reported as a percentage of total scale score.
5: Disability, or functional interference was captured using the interference subscales of the Neck Disability Inventory or the Brief
Pain Inventory and have been reported as a percentage of total scale score.
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Table 8 – Latent Growth Curve Analysis for pain severity and interference
dimensions
Model

AIC

BIC

Entropy

LMR-LRT adj (p)

2-class Pain Severity

2935.51

2983.58

0.79

81.03 (<0.01)

3-class Pain Severity

2927.64

2979.14

0.79

46.91 (0.21)

4-class Pain Severity

2911.76

2977.00

0.67

22.83 (0.53)

2-class Pain Interference

2952.30

3000.49

0.59

41.20 (<0.01)

3-class Pain Interference

2911.63

2973.59

0.68

46.12 (<0.01)

4-class Pain Interference

2874.52

2950.25

0.70

43.13 (0.09)
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Table 9 – Counts and proportions for pain interference trajectory based on (A) Pain
Interference % with 95% confidence intervals (axial and peripheral injuries) and
(B) Pain severity scores (out of 10) with 95% confidence intervals (axial and
peripheral injuries)
A
Trajectory

N (%)

Baseline*

1-month*

3-month*

12-month*

Rapid

34.9

4.68 (4.45, 4.91)

1.78 (1.62, 1.94)

0.27 (0.15, 0.38)

0.14 (0.05, 0.23)

Delayed

19.2

6.59 (6.23, 6.95)

5.66 (5.36, 5.95)

3.63 (3.37, 3.89)

0.51 (0.24, 0.77)

Minimal

45.9

6.39 (6.22, 6.56)

5.34 (5.19, 5.50)

4.69 (4.53, 4.85)

4.44 (4.25, 4.63)

Trajectory

N (%)

Baseline

1-month

3-month

12-month

Rapid

83.4

4.33 (4.15, 4.52)

2.99 (2.83, 3.15)

1.18 (1.06, 1.30)

0.65 (0.55, 0.75)

Minimal

16.6

5.70 (5.24, 6.16)

5.42 (5.00, 5.84)

5.20 (4.84, 5.55)

5.67 (5.35, 5.99)

B
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Table 10 – Cross-tabulation table of trajectory and 12-month BPI pain interference
outcomes (A) and BPI pain severity outcomes (B)
A
12-month
outcome

Rapid recovery
(%)

Delayed recovery
(%)

Minimal/No
recovery (%)

Total

<5% interference
(mild)

53 (91.4%)

29 (87.9%)

1 (1.1%)

83

5-20% interference
(mild-moderate)

5 (8.6%)

4 (12.1%)

56 (59.6%)

65

>20% interference
(moderate-high)

0 (0.0%)

0 (0.0%)

37 (39.3%)

37

Total

58

33

94

185

B
12-month outcome

Rapid recovery (%)

Minimal/No recovery (%)

Total

Pain = 0

75 (51.0%)

0 (0.0%)

75

Pain > 0

72 (49.0%)

38 (100%)

110

Total

147

38

185
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Figure 3 – Recovery Trajectories for Pain Interference in Axial and Peripheral
Injuries
Graphical representation of a 3-class LGCA model of pain interference recovery for axial
and peripheral injury over a 6-month follow-up period, where dashed lines indicate 95%
confidence intervals for each class. The x-axis denotes time and the y-axis denotes pain
interference expressed as a percentage out of 100. Rapid recovery (34.9%) is depicted as
having a moderate intercept and rapidly declining slope. Delayed recovery (19.2%) is
depicted as having a high intercept and steadily declining slope. Minimal or No
Recovery (45.9%) is depicted as having a high intercept and minimally declining slope.
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Figure 4 – Recovery Trajectories for Pain Severity for Axial and Peripheral Injuries
Graphical representation of a 2-class LGCA model of pain severity recovery for axial and
peripheral injury over a 6-month follow-up period, where dashed lines indicate 95%
confidence intervals for each class. The x-axis denotes time and the y-axis denotes their
pain severity score out of 10. Rapid recovery (83.4%) is depicted as having a moderate
intercept and steadily declining slope. Minimal or No Recovery (16.6%) is depicted as
having a high intercept and minimal slope.
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Chapter 4

4

Latent profile analysis of blood marker phenotypes and
their relationships with clinical pain and interference
reports in people with acute musculoskeletal trauma

4.1 Introduction
Chronic pain represents a substantial burden on patients and health systems, due in part to
its complexity and resistance to traditional medical and pharmaceutical treatments 1.
While progress in interdisciplinary care strategies has been made, effective pain
management remains a unique challenge 2. With chronic pain becoming a problem of
epidemic proportions 3, healthcare researchers and providers have turned their attention
towards the identification of mechanisms for early detection and intervention 4, 5.
Longitudinal modeling studies in both clinical 6 and population-level 7 samples have
identified trajectories of pain and recovery that most commonly indicate 15-25% of
participants report long-term, chronic or persistent pain and functional interference after
musculoskeletal trauma seemingly regardless of the body region affected 6, 8-11. In a prior
study (see chapter 2) we identified a 3-trajectory model of functional recovery from
musculoskeletal (MSK) trauma representing trajectories of rapid recovery (32.0% of the
sample), delayed recovery (26.7%), and minimal or no recovery (41.3%). Of note is that
Sterling and colleagues followed post-traumatic stress outcomes and also found a
qualitatively-similar 3-trajectory model as the best fit to the data. The identification of
consistent recovery trajectories provides new opportunities to characterize predictive
mechanisms.

Advances in research and technology has led to the re-emergence of a search for
biomarkers that may explain the onset or persistence of pain, though these have moved
from traditional approaches such as static structural imaging to more dynamic ‘omics’
approaches (e.g. genomics, transcriptomics, proteomics, metabolomics). The results of
such work has been mixed though evidence is mounting that dysfunction in some aspect
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of the omics cascade may represent a valuable biomarker of acute or chronic pain. In a
recent review of biomarkers of low back pain (LBP) 12, inflammatory mediators such as
high sensitivity C-reactive protein (hsCRP), tumor necrosis factor alpha (TNF-α), and
interleukin 6 (IL-6) were identified as having a potential role in the acute phase of LBP.
In the chronic phase Li et al 13 found that IL-10 was decreased while IL-6 was increased
in people with low back pain compared to matched controls. Conversely, Klyne et al 14
showed that IL-6 levels do not significantly differ between those with low back pain and
controls. They did, however, report a significant difference in IL-6 within the low back
pain group between those reporting high levels of pain and those reporting low levels of
pain. These studies suggest that there may be value in exploring blood-based proteins as
markers of distress and/or pain but that simple bivariate associations may not yield
consistent results.

The purpose of this study was to explore a theoretical position that 8 previouslyidentified blood-based protein/hormone biomarkers will explore meaningful variance in
pain-related outcomes after trauma but only when considered as clusters rather than
single bivariate associations. A secondary outcome was to explore the utility of the
biomarker clusters for predicting previously-derived clinical recovery trajectories.

4.2 Methods
Data from this observational cohort study were drawn from the longitudinal SYMBIOME
(Systematic Merging of Biology, Mental Health and Environment) databanking study
(clinicaltrials.gov ID no. NCT02711085). The study was approved by the office of
Human Research Ethics at Western University and the Lawson Health Research Institute,
and written, informed consent was obtained from all participants. Eligible participants
were identified by emergency or acute-care clinicians from an urgent care centre in
London, ON, Canada. After being medically discharged, a member of the research team
described the study, answered questions, enrolled and screened potential participants
prior to leaving the hospital. Two samples of antecubital blood were drawn into 4mL K2
EDTA BD vacutainer tubes by a trained phlebotomist and immediately stored on ice for
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transfer and storage at an immunity and proteomics lab. Prior to freezing the samples
were centrifuged for 10 minutes at 2000 x g, had plasma pipetted into up to 6 x 50μL
aliquots, and then both supernatant and pellet were stored at -80°C.
Participants were concurrently provided a package of self-report questionnaires that
included demographic metadata (age, sex, education level, work status, household
income, pre-existing pathology, BMI, and region of injury) and pain intensity and
functional interference through the Brief Pain Inventory 15. All participants provided
informed, written consent prior to participation.

Follow-up occurred at 1, 2, 3, 6 and 12 months from injury, with the biological samples
collected at baseline, 3, 6 and 12 months only. Participants were paid up to $300 in total
compensation for participation. For the purposes of this study, only the baseline blood
samples were analysed and interpreted for biomarker classes, and owing to attrition
recovery up to the 6-month follow-up was used as the final end point. Functional
recovery was measured using the pain and interference subscales of the BPI. The BPI is
one of the most widely used pain-interference scales globally 16 and has adequate
evidence of validity across many clinical populations including musculoskeletal pain 17.

4.2.1

Analysis of serum biomarkers

The target markers for this analysis were those shown previously to be associated with
pain, distress, or inflammation 18-24. Through a collaborative consultative process, eight
markers were specifically chosen: Brain-Derived Neurotrophic Factor (BDNF),
Transforming Growth Factor-beta 1 (TGFβ1), C-reactive protein (CRP), Tumour
Necrosis Factor-alpha (TNF-α), Interleukins 1-beta (IL-1β), 6 (IL-6) and 10 (IL-10), and
the stress hormone cortisol. Analyte concentrations in plasma were assayed using
multiplexed biomarker immunoassay kits according to manufacturers’ instruction for
Brain Derived Neurotrophic Factor (Human Premixed Multi-Analyte Kit, R&D Systems
Inc. cat. no. LXSAHM), Transforming Growth Factor-Beta 1 (TGFΒ1 Single Plex Magnetic
Bead Kit, EMD Millipore cat. no. TGFΒ1MAG-64K-01), Interleukins 1-β, 6, and 10 and
TNF-α (Human High Sensitivity T Cell Magnetic Bead Panel Multiplex Kit, EMD Millipore
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cat. no. HSTCMAG-28SK). A BioPlexTM 200 readout System was used (Bio-Rad
Laboratories, Hercules, CA), that uses Luminex® xMAPTM fluorescent bead-based
technology (Luminex Corp., Austin, TX). Levels were automatically calculated from
standard curves using Bio-Plex Manager software (v.4.1.1, Bio-Rad). Cortisol (Cortisol
Enzyme Immunoassay Kit, Arbor Assays cat. no. K003-H1/H5), and C-Reactive Protein (CReactive Protein (human) ELISA Kit, Cayman Chemical Company cat. no. 10011236) were
assayed following industry-standard approaches for Enzyme-Linked Immunosorbant
assay (ELISA). All assays were performed in duplicate with the value for analysis being
the mean concentration of the two runs.

4.3 Analysis
Participant characteristics were summarized descriptively (means and distributions or
proportions).

4.3.1

Pre-analysis of analytes

Prior to primary analyses we explored the distribution of the data both qualitatively and
statistically. Concentrations of all 8 analytes were significantly positively skewed and in
violation of normality via Kolmogorov-Smirnov tests. High outliers (>4SD above the
mean) or those for which the assay resulted in non-detectable (too low or too high)
concentrations were first removed. All concentrations were then square-root transformed
to reduce skewness, and then Z-transformed to place all concentrations on the same scale
with a mean of 0.0 and standard deviation of 1.0.

4.3.2

Bivariate associations

A matrix of all cross-product Pearson correlations between the 8 markers was created as
an exploratory step and to identify potential problems with collinearity in cluster analysis
(r > 0.80). There was no statistical correction for multiple comparisons, accepting the
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potential for alpha error rather than prematurely rejecting potentially important findings
at this exploratory stage.

4.3.3

Profile Analysis

Meaningful clusters in the data were identified with maximum likelihood estimation
(MLE)-based latent profile analysis (LPA) as previously described 25 using MPlus
software v6.12 (Muthen and Muthen, Los Angeles, USA). Using all 8 target biomarkers,
a series of models were constructed, starting with a single profile (termed ‘class’) and
increasing until model fit no longer improved in a meaningful way, the LPA estimation
could no longer derive a mathematically definable model, one of the latent classes
possessed fewer than 10% of participants, or the class structure did not make clinical
sense. The fit indicators of interest were the Akaike Information Criterion (AIC) 26-28, the
Bayesian Information Criterion (BIC) 26-28, entropy 27, and the adjusted Lo-MendellRubin likelihood ratio test (LMR-LRT)26, 28 while considering solutions that provide
generally strong posterior classification probabilities (ideally ≥0.85). While no set criteria
exist for deeming model fit acceptable 28, the cluster solution that provides the lowest
AIC and BIC and the highest entropy value (acceptably >0.70, ideally >0.80) that also
conforms to theory is generally considered optimal 29. The LMR-LRT is used to
statistically compare the fit of the k cluster solution with that of the k-1 class solution.
When fit no longer statistically improves (p>0.05) with the addition of a new class, the
solution with the smaller number of classes is generally accepted 28, 30.

In the interest of parsimony, once an overall class solution was determined biomarkers
were then systematically eliminated to obtain the simplest discriminatory model. To start,
mean differences in square-root transformed marker concentration were explored across
the identified classes using one-way analysis of variance (ANOVA). The marker with the
smallest interclass differences was eliminated first, followed by the next smallest, and so
on until the simplest model remained that still showed good fit indicators in LPA. The
intention was that each of the blood markers defining the final class solution should show
a significant difference between the groups.
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4.3.4

Recovery and outcome analysis

After LPA each participant was assigned to one of the identified classes based on relative
blood marker concentration. Pain-related 12-month outcome data was trichotomized for
pain interference (<5% mild interference, 5-20% moderate interference, >20% severe
interference) and dichotomized for pain severity (pain = 0, pain > 0). Biomarker classes
were then compared against these pain-related outcome groups using χ2 analysis.

4.3.5

Sample size estimation

There is little guidance in the literature for optimal sample size in MLE-based LPA. Prior
to the exploratory analyses described herein there was also no clear existing evidence to
inform the likely number of clusters or the relative proportions or communalities to assist
with sample estimation. Therefore we adopted the general position in the field that a
minimum of 100 samples is a minimum for meaningful results, and continued to position
the analyses as discovery (exploratory) in nature, that is, hypothesis-generating rather
than hypothesis-testing.

4.4 Results
Table 11 provides the characteristics of the study population. There were 109
participants in the SYMBIOME database who provided blood samples within 3 weeks of
MSK trauma. After assay, data for 3 participants were removed as all analytes were not
detectable or out of range of the kits. Mean age of the remaining n=106 was 44.6 years
and 58.5% of the sample was female. The modal mechanism of injury was reported as
‘other’ and 74.3% of the sample reported the primary region of injury as the upper or
lower extremity (vs. the axial spine). Pain severity and interference at inception was
moderate (Mean Severity = 4.5/10, SD = 2.0; Mean Interference = 28.6/70, SD = 16.8).
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Table 12 is the cross-product correlation matrix between all biomarker pairs after
removal of outliers and square root transformation. BDNF and TGF-β1 demonstrated the
strongest association (r = 0.74, p<0.01). Cortisol and CRP did not appear to be
associated with any other biomarker while IL-6 and IL-1β were significantly correlated
with all markers except those two.

Table 13 shows the results of the LPA models with associated fit indicators for the
models tested. The final class solution was a 3-class model as it showed a meaningful
improvement over a 2-class solution based on relevant fit indicators (AIC = 2257.31, BIC
= 2348.82, Entropy = 0.83, LMR-LRT = 28.08, p=0.08). Figure 5 show the relative
concentrations of all 8 markers in the 3 class model. After settling on the 3-class model,
analytes were removed in a systematic fashion based on total interclass differences. CRP
(F(2,108) = 0.14, p=0.87) and cortisol (F(2,108) = 2.34, p=0.10) displayed the smallest
interclass mean differences (Fig.1) and were eliminated first. Table 13 also shows the
model fit adjustment of the 3-class latent profile solution with the sequential elimination
of biomarkers. TNF-α (F(2,108) = 10.65, p<0.01), IL-6 (F(2,108) = 11.40, p<0.01), and
IL-10 were also removed, in that order, each time retesting model fit and posterior
classification probabilities. The remaining 3 markers were BDNF, TGFβ1 and IL-1β.
BDNF and TGFβ1 were both discriminative across the 3 classes, while IL-1β provided
improved discrimination between the two lower concentration classes. The decision to
retain IL-1β despite acceptable model fit is described in the discussion section. The final
model indicated a 3-class solution that could be adequately described by 3 of the 8
markers (AIC = 827.41, BIC = 865.09, Entropy = 0.80, LMR-LRT = 34.08, p=0.03). The
3 classes were labeled according to the relative concentrations of the 3 markers as: Class
1 = Low concentration of all markers (33.9% of the sample), Class 2 = Average
Concentration of all markers (47.7%), and Class 3 = High concentration of BDNF and
TGFβ1 (18.3%). Figure 6 shows relative (Z-transformed) concentrations graphically and
Table 14 shows the raw (non-transformed) values with 95% confidence intervals.

With each participant assigned to the most likely biomarker class based on posterior
probabilities, the sample was split into 3 groups. BPI Pain Severity and Pain Interference
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scores captured at 6-month follow-up were compared across groups using chi-square
analysis. Table 15 shows the frequencies of the final biomarker classes across relevant
recovery outcomes of pain interference/disability (Table 15A) and severity (Table 15B).
The majority of participants seemed to recover from their injuries with respect to both
pain disability (75.5%) and severity (62.4%). In Table 15A, both mild and moderate
interference contain a small minority of participants that show high BDNF/TGF-β1
(13.8% and 14.3%, respectively). Those with severe, persisting disability however,
display an increased trend (40%) towards high BDNF/TGF-β1 (χ2 = 5.85, df = 2, p =
0.06, Fisher’s exact test).

Similarly in Table 15B, those with persisting pain at 12

months (pain > 0) have a greater proportion of high BDNF/TGF-β1 (26.3%) compared to
those who have no pain (10.3%) at 12 months (χ2 = 3.86, df = 1, p = 0.049).

4.5 Discussion
We have presented a first step towards derivation of a potentially useful panel of
immunological, neurotrophic, and endocrine markers assayed from serum for use in posttraumatic pain research. Through a multi-step approach to latent profile analysis, a 3class solution was identified that could be adequately described by 3 of 8 markers:
BDNF, TGFβ1 and IL-1β, though at least two other markers (IL-6 and IL-10) also
showed some significant discriminative accuracy between the classes. Further,
participants assigned to the class representing the highest mean BDNF and TGFβ1
concentrations also tended to rate higher on self-rated scales of pain-related functional
interference when measured 12 months post-trauma. Although the difference between
pain interference groups was non-significant from a traditional standpoint, it would be
premature to dismiss these findings considering a similar result in pain severity and the
exploratory nature of this study.

As shown in Figures 1 and 2, an argument could have been made for removing IL-1β
from the final model and retaining only TGFβ1 and BDNF, though the strong correlation
between these two markers (Table 12) led us to retain a third marker for better
discriminative accuracy between Class 1 and Class 2, and to allow greater opportunities
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for exploration of potential mechanisms behind the biomarker/clinical outcome
associations found here. Both IL-10 and IL-6, and to a lesser extent TNF-α, could also
have been retained as they too discriminated between the two lower concentration
classes, but IL-1β provided the greatest discriminative accuracy (largest between-class
mean difference) and was therefore chosen as the third marker. To our knowledge this is
the first time that these 3 markers, arguably up to 6 markers, have been shown to interact
as a panel that may have clinical utility if the findings can be replicated in an independent
sample. It is notable that the only two markers that showed no between-class differences
(CRP and Cortisol) were also those that showed no meaningful association with any of
the other 6 markers (Table 12). This should not be mistaken as indicating that these
markers are unimportant in research into pain and trauma, rather that through cluster
analysis they did not contribute important explanatory utility to the classes identified
herein.

BDNF is a small peptide that is involved in myriad functions related to survival, growth
and plasticity of neurons and it acts as a key regulator of learning and memory 31. It
carries out this activity by binding to its receptor tyrosine kinase B (TrkB) and activating
signalling cascades involved in gene transcription for proteins of stress and plasticity 3133

. TGF-β1 is a ubiquitous, pleiotropic cytokine that, along with its immunomodulatory

function, is involved in cell growth, development, angiogenesis, and wound healing 34.
TGF-β1 has been shown to play a role in the long-term facilitation of neuronal activity
and transmission 35. Both BDNF and TGF-β1 do not seem to display any significant
short term effects on sensory neurons, but they appear to have a role in facilitating longterm signaling by affecting new growth at sensory neuron synapses 35, 36. With regard to
pain, Sikandar and colleagues have demonstrated that primary afferent-derived BDNF
may be involved in the transition from acute to chronic pain. By applying an
inflammatory stimulus to mice, they showed that conditional BDNF knockout mice do
not develop an ongoing mechanical hyperalgesia 24. Similarly, Richner and colleagues
have shown that BDNF, via TrkB receptors, can reduce inhibition at the spinal dorsal
horn by downregulating the expression of a protein known as KCC2 37. By inhibiting this
BDNF-regulated pathway, they were able to prevent the decrease of KCC2 and impair
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mechanical allodynia. TGF-β1, with its ability to suppress immune activity and promote
endogenous opioid signaling, appears to have a protective effect against the development
of chronic neuropathic pain 38. The association between BDNF and TGF-β1 appears to
have prior empirical support, at least in animal models. Sometani et al have shown that
TGF-β1 administered to cortical neurons of the rat increases BDNF and TrkB expression,
suggesting that BDNF may require TGF-β1 in order to carry out its neurotrophic effects
39

. Both BDNF and TGF-β1 also appear to regulate the Gadd45 family of enzymes

which have been implicated in psychiatric diseases 40. Although it is unclear in what
capacity BDNF and TGF-β1 are exerting their influence in persistent disability and pain
in humans, their association is at least biologically plausible.
Despite the significance of BDNF and TGF-β1, at this early stage of research it is advised
that future studies consider incorporating all of the biomarkers explored here. Cytokines
often act synergistically such that their effectiveness is substantially increased when
working in concert with one another 41. Together they can affect multiple systems
through peripheral and central crosstalk mechanisms to influence immune, endocrine and
neuronal functioning 42, 43. For example, prior work by Sterling and colleagues
demonstrated a potential role for both TNF-α and CRP, wherein the latter appeared to
show some discriminative accuracy in identifying those with more severe symptoms
following whiplash injury 44. Additionally, Li et al 13 and Klyne et al 14 found that IL-6
may also be involved in discriminating between control and low back pain, and within
low back pain groups, respectively.

The effects in our study may be related to the simultaneous consideration of multiple
markers in the same class. Many prior studies, including a recent companion manuscript
from the same dataset (see chapter 1), we showed that in isolation none of the 8 markers
explored here were associated with clinical pain or interference levels, though several
potential moderating effects of psychosocial variables were identified. We believe
however that it is the multivariate cluster nature of the results from this latent profile
analysis that will prove more valuable. In the same way that a single genetic
polymorphism is unlikely to explain important variance in a clinical outcome but gene x
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gene interactions are more likely, the expression of certain proteins, at certain levels, in
the same person appears as though it may be a more fruitful direction for exploration. In
exploring this hypothesis we are working at the ‘proteomics’ level of the ‘omics’ cascade,
downstream from genomic and transcriptomic processes but upstream from
metabolomics. Future research directions could use these results and then move along
that cascade in either direction to further explain these findings. It is important to reiterate
that this has been considered exploratory research and needs replication, and that despite
some biological plausibility, association is not causation.

There are some important limitations of this study to consider. First, blood was drawn
using venipuncture which may involve increased anxiety for some. All participants were
notified at screening and prior to consent of the requirement for repeated blood draws
which may have been sufficient to eliminate those with needle-based anxieties. Second,
blood was drawn as participants presented to the urgent care centre regardless of the time
of day. This allowed for a more accurate “baseline” sample to be taken as close to the
time of trauma as possible, but it does not take into account the known diurnal variations
in some of these biomarkers, specifically cortisol 45 and CRP 46. If sample collection had
occurred at the same time each day, this may have shown a greater overall effect of the 8
biomarker model. Lastly, as this was an exploratory study, we have not attempted to
build more complex multivariate models, including for example sex, age, or
psychological distress. Our prior work supports the notion that the associations shown
here may be moderated by other important person-level variables that require larger
datasets to properly explore. This represents an important step for future studies as
analyzing biomarker concentrations in isolation may be an oversimplification of their role
in persistent pain.

In conclusion, we have presented an exploratory study of immune, neurotrophic and
endocrine biomarkers in a population of people in the acute stage of non-catastrophic
musculoskeletal trauma using latent profile analysis. Our results show that a 3-class
profile solution appears to be the most statistically sound. Interestingly 6 out the 8
biomarkers showed some potential to discriminate between different classes, with cortisol
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and CRP being the only exceptions. Classes were organized based on increasing serum
biomarker concentration where the third class was characterized by high BDNF/TGF-β1.
Although recovered populations are not significantly different in their levels of BDNF
and TGF-β1, those who experience persisting disability or pain are more likely to have
higher levels in serum. These findings, if used in combination with other self-report
measures of pain and distress, may provide a simple biopsychosocial approach to
phenotyping pain in a clinical population.
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Table 11 – Characteristics and baseline values of SYMBIOME participants in this
analysis
N = 109
Sex (% female)

58.5%

Age (mean, range)

44.6 years (18 to 66)

BMI (mean, range)

26.4 kg/m2 (14.4 to 51.5)

Primary Region of Injury (%)
Axial

25.7%

Extremity

74.3%

Mechanism of injury (%)
Motor vehicle injury

7.1%

Fall

28.6%

Hit by person or object

19.4%

Awkward lift or twist

14.3%

Other

30.6%

Brief Pain Inventory at Inception (mean, range)
Pain Severity (/10)

4.5 (0 to 8)

Pain Interference (/70)

28.6 (0 to 67)
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Table 12 – Cross-product correlation matrix of all 8 analytes (Pearson’s r) after
square-root transformation

IL-1β

IL-6

IL-10

TNF-α

TGF-β1

BDNF

CRP

Cortisol

0.47**

0.53**

0.42**

0.34**

0.31**

0.03

-0.06

0.47**

0.34**

0.25*

0.21*

-0.01

0.01

0.42**

0.19*

0.17

-0.09

-0.10

-0.01

0.18

0.02

0.11

0.74**

-0.16

0.11

-0.01

0.16

IL-6
IL-10
TNF-α
TGF-β1
BDNF
CRP

-0.05

*: correlation is significant at the p<0.05 level, **: correlation is significant at the p<0.01 level.
Biomarkers: Brain-Derived Neurotrophic Factor (BDNF), Transforming Growth Factor-beta 1 (TGF-β1),
C-reactive protein (CRP), Tumour Necrosis Factor-alpha (TNF-α), Interleukins 1-beta (IL-1β), 6 (IL-6) and
10 (IL-10), and cortisol.
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Table 13 – Fit Indicators for latent profile analysis and class assignment
AIC

BIC

Entropy

LMR-LRT (p)

2 class

2298.77

2366.06

0.78

90.80 (0.07)

3 class

2257.31

2348.82

0.83

58.08 (0.08)

4 class

2231.06

2346.79

0.89

43.23 (0.30)

3 class (- CRP)

1986.71

2067.45

0.83

57.81 (0.058)

3 class (- cortisol)

1678.22

1748.20

0.82

56.22 (0.054)

3 class (- TNFα)

1384.94

1444.15

0.81

47.06 (0.053)

3 class (- IL6)

1121.54

1169.99

0.80

39.44 (0.029)

3 class (- IL10)

827.41

865.09

0.80

34.08 (0.033)

3 class (- IL1β)

539.24

566.16

0.81

27.44 (0.025)

Akaike Information Criterion (AIC), Bayesian Information Criterion (BIC), Entropy and Lo-MendullRubin Adjusted Likelihood Ratio Test (LMR-LRT). Values highlighted in BOLD indicate the preferred
class for analysis. Biomarkers: Brain-Derived Neurotrophic Factor (BDNF), Transforming Growth Factorbeta 1 (TGF-β1), C-reactive protein (CRP), Tumour Necrosis Factor-alpha (TNF-α), Interleukins 1-beta
(IL-1β), 6 (IL-6) and 10 (IL-10), and cortisol.
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Table 14 – Mean (raw, untransformed) concentrations of the analytes across the 3
classes identified through LPA

IL-1β

Overall mean (95%CI)

Class 1 (n = 42)

Class 2 (n = 47)

Class 3 (n = 20)

F (p)

2.71 (2.43, 2.99)

1.32 (1.07, 1.58)

3.46 (3.14, 3.77)

3.19 (2.52, 3.87)

19.75
(<0.01) 1

(pg/mL)
BDNF

3.55 (3.00, 4.09)

1.78 (1.22, 2.34)

3.08 (2.71, 3.46)

8.65 (7.51, 9.80)

(<0.01) 2

(ng/mL)
TGF-β1

24.45 (21.11, 27.79)

16.96 (12.22, 21.70)

21.78 (19.02, 24.54)

46.67 (35.74, 57.60)

21.12 (18.08, 24.16)

15.7 (11.9, 19.5)

23.1 (18.5, 27.7)

27.8 (18.2, 37.4)

92.17 (80.05, 104.29)

70.1 (56.9, 83.2)

101.9 (81.5, 122.2)

115.6 (80.3, 150.8)

5.61 (5.08, 6.13)

4.9 (3.9, 5.8)

6.0 (5.4, 6.7)

6.1 (4.6, 7.5)

(pg/mL)
CRP

2.77
(0.07)

3.34 (2.65, 4.01)

3.22 (2.24, 4.21)

3.36 (2.29, 4.44)

3.48 (1.41, 5.54)

(mg/L)
Cortisol

4.81
(0.01)1

(pg/mL)
TNF-α

6.06
(<0.01)1

(pg/mL)
IL-6

67.14
(<0.01) 2

(ng/mL)
IL-10

182.92

0.00
(1.00)

12.04 (10.58, 13.49)

10.44 (8.65, 12.22)

13.42 (10.75, 16.08)

12.05 (8.68, 15.43)

(μg/dL)
1: The mean concentration was significantly lower in Class 1 compared to the other two groups. 2: The
mean concentrations of both BDNF and TGF-β1 were significantly different across all 3 groups. Statistical
tests were one-way ANOVA with Tukey’s post-hoc test using square-root transformed data to reduce
deviations from normality. BOLD are the 3 markers retained in the final model solution. Biomarkers:
Brain-Derived Neurotrophic Factor (BDNF), Transforming Growth Factor-beta 1 (TGF-β1), C-reactive
protein (CRP), Tumour Necrosis Factor-alpha (TNF-α), Interleukins 1-beta (IL-1β), 6 (IL-6) and 10 (IL10), and cortisol.

1.99
(0.14)

106

Table 15 – Crosstabulation of biomarker classes with 6-month outcomes in pain
interference (A) and severity (B)
A
BPI Pain Interference

Low-Mod BDNF/TGFβ1

High BDNF/TGF-β1

Total

Mild interference (<5%)

69

11

80

Mod Interference (5-20%)

18

3

21

Severe Interference (>20%)

2

3

5

Total

89

17
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BPI Pain Severity

Low-Mod BDNF/ TGFβ1

High BDNF/TGF-β1

Total

No Pain (Pain = 0)

61

7

68

Persisting Pain (Pain > 0)

28

10

38

Total

89

17
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B
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Figure 5 – Graphical representation of the 3-class latent profile solution along with
the frequencies of each class.

All 8 target markers presented in a 3-class profile solution were labeled accordingly: Class 1 =
Low concentration of all markers (32.8% of the sample), Class 2 = Average Concentration of all
markers (49.0%), Class 3 = High Concentration of BDNF and TGF-β1 (18.2%). Relative
concentration represents z-transformed values. Biomarkers: Brain-Derived Neurotrophic Factor
(BDNF), Transforming Growth Factor-beta 1 (TGFβ1), C-reactive protein (CRP), Tumour
Necrosis Factor-alpha (TNF-α), Interleukins 1-beta (IL-1β), 6 (IL-6) and 10 (IL-10), and cortisol.
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Figure 6 – Graphical representation of the 3-class latent profile solution adequately
described by 3 of the 8 markers.

Classes were labelled accordingly: Class 1 = Low concentration of all markers (41.5% of the
sample), Class 2 = Average Concentration of all markers (42.4%), and Class 3 = High
concentration of BDNF and TGF-β1 (16.1%). Relative concentration represents z-transformed
values. Biomarkers: Interleukin-1β (IL-1β), Brain-Derived Neurotrophic Factor (BDNF), and
Transforming Growth Factor β1 (TGF-β1).
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Chapter 5

5

Summary

In an essay entitled “Meditation in a toolshed”1, author C.S. Lewis describes standing
inside a shed and observing a beam of sunlight that has entered through a crack in the
doorway. Standing beside the doorway, only the beam itself is visible inside the
darkened space with specks of dust illuminated along its path. When he steps into the
path of the beam however, and looks along the light through the crack in the door, he sees
the tree outside, the sky, and the sun far off in the distance. These are two very different
experiences that result in separate conclusions. He uses this example to illustrate the
difference between “looking at” and “looking along”, while making the comparison
between objective and subjective experience. But which one represents the truth? Lewis
argues that both perspectives are essential to understanding the greater questions of
human existence.
The idea of addressing things in a holistic fashion is certainly not a new one. Lewis’
essay was first published in 1970, and though it spoke to questions of a more
transcendental nature, the underlying concept was also beginning to emerge in the
medical field. Engel first proposed the biopsychosocial model as an alternative to the
biomedical model in 1977; where Engel outlines the importance of considering the whole
individual rather than giving automatic preference to the objectivity of a medical expert2.
Even Melzack’s neuromatrix model3, upon which this dissertation is conceptually based,
is now almost three decades old. Yet chronic pain remains a prevalent issue in our
society with no single solution, which emphasizes both its universality and subjectivity.
The purpose of this dissertation was to introduce only the initial phase of the
SYMBIOME project, whose overarching goal is to reconcile the biological,
psychological and social dimensions of the experience we know as pain. These chapters
represent the first of our attempts to combine the perspectives of “looking at” and
“looking along” musculoskeletal pain in an effort to better understand this very
intersectional problem.
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Chapter 2 demonstrates the results of a wide-ranging moderator analysis in the context of
functional outcomes (pain interference and pain severity). Taking psychological and
social moderators into consideration has an effect on the relationships between
biomarkers and pain. In relation to pain severity, TNF-α, TGF-β1, and CRP were
moderated by the effects of employment prior to trauma, pre-existing psychopathology,
and biological sex, respectively. In relation to pain interference, IL-1β, cortisol, TGF-β1,
CRP, and IL-6 were moderated by the effects of pre-existing pain conditions, peritraumatic fear, the region of injury (axial vs peripheral), and peri-traumatic stress. These
results support the claim that physiological factors are tied to pain through more than
simple bivariate relationships. The context of the musculoskeletal trauma, both the
personal and social context, can affect the behavior of biological systems. The greater
implication of this work is that it advocates for a comprehensive phenotyping when
dealing with pain, as opposed to the simple presence or absence of inflammatory
regulators as can be done with certain arthritic conditions.
Chapter 3 demonstrates the results of latent growth curve analysis in determining the
recovery trajectories of acute non-catastrophic musculoskeletal pain in the context of pain
interference and severity over the course of 12 months from the time of the initial trauma.
With pain interference as the relevant outcome, 3 distinct trajectories emerged wherein
people would either rapidly recover, have a delayed recovery (but still reach full recovery
by 12 months), or experience minimal to no recovery at all. Pain severity favored a 2trajectory model with rapid recovery or minimal to no recovery. The classification of
recovery group depended on both the initial baseline symptoms and the relative rate of
symptom decline. Both recovery outcomes appeared to stabilize after a period of 3
months. The implications of this work are that recovery cannot adequately be measured
by initial symptom severity alone. Recovery trajectories may help guide prognostication
efforts but it is recommended that they be used in association with other measures.
Future longitudinal research may wish to consider both the recovery trajectory and distal
outcomes together in order to develop accurate groupings or classes.
Chapter 4 demonstrates the results of latent class analysis and growth mixture modeling
when applied to relevant biomarkers of pain. This chapter presents the initial derivation
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of a panel of 8 biomarkers (TNF-α, IL-1β, IL-6, CRP, IL-10, cortisol, BDNF, and TGFβ1) that may have the potential to discriminate between functional recovery outcomes.
Using this panel of immune, neurotrophic and endocrine regulators, 3 meaningful groups
or classes were identified. These groups could be adequately defined by using only 3 of
the 8 markers (IL-1β, BDNF, and TGF-β1) where classes were organized by low
concentration of markers in serum, average concentration, or high concentration of
BDNF and TGF-β1. Participants assigned to the high concentration class at baseline
were more likely to score higher on self-report measures of pain and disability in their 6month outcomes. These results suggest that biomarkers of immune, nervous and
endocrine function may provide a useful prognostic tool of persistent symptoms when
used in combination with other measures of pain in the context of acute musculoskeletal
trauma.
A clinical summary of this work suggests that person-level variables such as pre-existing
psychological conditions, employment status, and sex may play a role in the perceived
severity of pain. However, pre-existing pain conditions, the location of trauma (spinal vs
peripheral), and presence of fear or stress at the time of trauma may be more relevant to
one’s perceived disability. Unlike what has been suggested in previous literature, initial
symptom severity alone may not be adequate to predict long-term outcomes. Although
people who rapidly recover will likely have lower levels of initial severity or disability, it
is still possible to experience a full recovery with higher baseline symptoms. These
individuals (as indicated by the “delayed recovery trajectory” in chapter 3) may recover
at a slower rate, but still be fully functional by 12 months. Although it is not entirely
clear which factors will distinguish between delayed and minimal recovery, the data
suggests that significant improvements in interference can occur by 1-3 months for those
in the delayed trajectory. Close monitoring of the aforementioned physical and
psychosocial variables in the initial 3 months will be relevant for interdisciplinary
treatment and the potential for early intervention. There also appears to be more
variability in pain interference compared to severity as recovery tends to occur in 3 (as
opposed to 2) different trajectories. This suggests that there may be more change
associated with functional ability over the course of rehabilitation even if symptoms of
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severity remain relatively stable. Although physical therapy cannot directly benefit from
detecting clusters of biomarkers in serum at this time, it may be possible in the future to
develop a composite score of pain that includes specific clusters of biomarkers, relevant
person-level variables, and current pain measurement scales.
Although this dissertation is by no means a definitive formula on a systems-based
approach to pain research, it represents our efforts to lay the groundwork for the deep
clinical phenotyping of pain. By understanding the nature of the interactions between
systems and the relevant risk factors therein, it may be possible to develop a predictive
algorithm that can accurately identify those at risk of developing chronic pain. This
knowledge may also be used toward the development of individualized treatment plans
for those who suffer from chronic pain and require strategic, interdisciplinary
management.

5.1 Future Directions
As stated previously, this project is merely the initial stage in the development of a “pain
phenotype”. As a simple strategy to further develop this prognostic phenotype, future
research may consider a deeper exploration of sex and gender as it relates to the
development of pain. Previous studies in the field of pain and gender have shown that
females bear a greater burden of chronic pain than males4. This difference is only
partially accounted for by the contributions of social factors such as education, economic
stability, and age5. Further research may link differences in internal functioning with the
age and sex of the participant. Other considerations that should be taken into account are
gender roles and expectations. A common, pre-conceived notion is that the female role is
associated with lower pain tolerance and greater likelihood to report pain6. These notions
however are influenced by gender constructs and gender itself can be considered a
continuum6. This area represents another relevant dimension in capturing the experience
of pain especially since women are underrepresented in pain medicine7.
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From an intervention perspective, cannabinoids represent a class of compounds which
may possess the potential to modulate a number of processes related to pain. Research
has shown that cannabinoid compounds have significant modulatory effects on both the
immune 8, 9 and nervous systems 10, along with higher brain functions 11. External
cannabinoids are able to exert their effects due to the presence of an internal system of
cannabinoid receptors and endogenously-produced cannabinoid compounds (i.e.
endocannabinoids) 12, 13. This endocannabinoid system is closely linked with major
physiological functions as cannabinoid receptors are located throughout the body14. Once
these receptors are activated by either external cannabinoid compounds or
endocannabinoids, they affect a number of different tissues to influence anxiety, pain,
nausea, and inflammation 13, 15 . Despite this extensive involvement in regulating
function, a number of genetic variations have been identified in the genes responsible for
cannabinoid activity and cannabinoid breakdown in the body (i.e. metabolism). Although
the results are not conclusive, these variations may influence the efficacy of cannabinoids
in different individuals 16. To address these individual variations, pharmacogenetics
represents a promising new tool in the development of personalized medicine. It involves
the screening of specific genes associated with a given drug’s activity and metabolism to
determine a person’s potential responsiveness to the drug itself 17. This technology has
been used to develop personalized pain treatments, but has yet to be implemented on a
wide scale due to a lack of knowledge on translating genetic profiles into clinical action
17

and the associations between gene targets and functional traits 18. Application of this

genetic screening technology within known recovery groups in musculoskeletal pain may
help to identify novel gene-trait associations and inform cannabinoid treatment decisions
going forward.

114

5.2 References
1.

Lewis CS. Meditation in a Toolshed. God in the Dock. 1970;2000:212-215.

2.

Lindau ST, Laumann EO, Levinson W, Waite LJ. Synthesis of scientific disciplines
in pursuit of health: the Interactive Biopsychosocial Model. Perspect Biol Med.
Summer 2003;46(3 Suppl):S74-86.

3.

Melzack R. Phantom limbs and the concept of a neuromatrix. Trends Neurosci. Mar
1990;13(3):88-92.

4.

Reitsma ML, Tranmer JE, Buchanan DM, VanDenKerkhof EG. The epidemiology
of chronic pain in Canadian men and women between 1994 and 2007: results from
the longitudinal component of the National Population Health Survey. Pain
Research and Management. 2012;17(3):166-172.

5.

Meana M, Cho R, DesMeules M. Chronic pain: the extra burden on Canadian
women. BMC women's health. 2004;4(1):S17.

6.

Alabas O, Tashani O, Johnson M. Effects of ethnicity and gender role expectations
of pain on experimental pain: A cross‐cultural study. European Journal of Pain.
2013;17(5):776-786.

7.

Doshi TL, Bicket MC. Why aren't there more female pain medicine physicians?
Regional Anesthesia & Pain Medicine. 2018;43(5):516-520.

8.

Schatz AR, Lee M, Condie RB, Pulaski JT, Kaminski NE. Cannabinoid receptors
CB1 and CB2: a characterization of expression and adenylate cyclase modulation
within the immune system. Toxicol Appl Pharmacol. Feb 1997;142(2):278-287.

9.

Klein TW, Newton C, Larsen K, et al. The cannabinoid system and immune
modulation. J Leukoc Biol. Oct 2003;74(4):486-496.

115

10.

Mackie K. Distribution of cannabinoid receptors in the central and peripheral
nervous system. Handb Exp Pharmacol. 2005(168):299-325.

11.

Mancini G, Horvath TL. Mitochondria Bioenergetic and Cognitive Functions: The
Cannabinoid Link. Trends Cell Biol. Jun 2017;27(6):391-392.

12.

Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of
pharmacotherapy. Pharmacological reviews. 2006;58(3):389-462.

13.

Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce? Nature
reviews Drug discovery. 2008;7(5):438-455.

14.

Jordan CJ, Xi ZX. Progress in brain cannabinoid CB2 receptor research: From
genes to behavior. Neurosci Biobehav Rev. Mar 2019;98:208-220.

15.

Wu J. Cannabis, cannabinoid receptors, and endocannabinoid system: yesterday,
today, and tomorrow. Acta Pharmacol Sin. Mar 2019;40(3):297-299.

16.

Hryhorowicz S, Walczak M, Zakerska-Banaszak O, Slomski R, SkrzypczakZielinska M. Pharmacogenetics of Cannabinoids. Eur J Drug Metab
Pharmacokinet. Feb 2018;43(1):1-12.

17.

Caudle KE, Gammal RS, Whirl-Carrillo M, Hoffman JM, Relling MV, Klein TE.
Evidence and resources to implement pharmacogenetic knowledge for precision
medicine. Am J Health Syst Pharm. Dec 1 2016;73(23):1977-1985.

18.

Ting S, Schug S. The pharmacogenomics of pain management: prospects for
personalized medicine. J Pain Res. 2016;9:49-56.

116

Appendices
Appendix A: Ethics approval for ongoing review of the SYMBIOME project

117

Appendix B: Letter of Information

May 28, 2015
Principal Investigator: Dr. David Walton
Funding source: Western internal funding, CIHR bridge grant, Canadian Pain Society

Letter of Information
Modeling recovery after traumatic injuries

Dear Sir/Madam,
Thank you for your time in reviewing this letter of information and for considering participation in our
study. Please be sure to read this letter in its entirety and have any questions you may have answered to
your satisfaction before consenting to participate.
Why am I being invited to participate?
You are being invited to participate because you have indicated that you are a male/female between the
ages of 18-65 and are seeking care from emergency, medical or rehabilitation services for a recent
accident or injury to your muscles, bones or ligaments, or because you have responded to one of the
posted advertisements for this study.
You are not eligible for this study if any of the following apply to you. Please tell the research coordinator
if any of these apply:
1. Severe gingivitis, periodontal disease, active dental caries (tooth decay), or any other active oral
condition
2. Actively undergoing cancer treatment
3. Are currently experiencing an infection or illness (cold, flu, fever, etc.)
4. Are currently taking antibiotics or have taken antibiotics within the past week
5. You are a smoker or have been a smoker within the past year
6. You have Diabetes, either Type I or Type II
7. You currently have stomach ulcers, Celiac or Inflammatory Bowel Disease (Ulcerative colitis or
Crohn’s Disease)
What is this study about?
We are trying to understand the process of recovery over the 6 months following a traumatic injury, and
to identify things (factors) that may explain why people differ in how they recover after these events. We
will be collecting information including the nature of your injury, your biology, psychology, and past
experiences all in the same period. Our goal is to not only improve understanding of how people recover
following different types of injuries, but what factors influence that recovery. By identifying important
factors we will start to work on developing new ways to treat those factors and eventually improve the
likelihood of successful recovery for people injured in the future.
What will I be asked to do?
If you agree to participate, you will be provided with a package that includes almost all of the data
collection instruments that you will be asked to complete on your own at home starting at least 48 hours
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after your injury. The procedures include questionnaires for you to complete and different vials into
which you will provide saliva and a stool sample. Once collected, the samples can be stored in your home
freezer until a member of the research team comes to pick them up. The questionnaires will be repeated
monthly for 6 months after your injury and the biological sampling will be repeated after 3 and 6 months.
After the 6th month, your participation in the study will be complete. Below you will find more detailed
information on the types of data instruments in this study.
1.

2.

3.

4.

A set of questionnaires that will ask you about a variety of different things. These include: i)
your age, sex, work and educational status, ii) the nature of your injury (type of injury, when it
occurred, how long ago it occurred, a brief description of the injury itself), iii) your medical and
legal involvement (if any), iv) experiences from your childhood, including bullying and home
environment, v) recent stressors you may have experienced, vi) the stress you have experienced
as a result of your injury, vii) the type and amount of symptoms and interference you have
experienced as a result of your injury.
Drool/Saliva (part 1) – You will receive 3 specialized test tubes with sterile cotton swabs in each.
You will start on a day that is convenient to you, preferably within 5 days of completing your
questionnaires. A pamphlet explaining all procedures is included with the instruments. This
pamphlet should be read in its entirety. The tubes with the cotton swabs are to be used 3 times
during the same day – once immediately upon waking, again 20-30 minutes after waking, and
again mid-afternoon between 2pm and 4pm. This will require you to chew the cotton swab for
about 10 seconds before returning it to the test tube, sealing it and placing it in your freezer.
Drool/Saliva (part 2): You will receive a specialized test tube into which you will spit or drool a
small amount of saliva BEFORE your nightly (bedtime) routine, before brushing but at least 2
hours after eating. Once completed, this and the other samples can be stored in your residential
freezer until retrieved by a member of the research team.
Serum: A trained researcher will draw 3cc of blood from the vein on the front of your elbow.

The following two components are optional.
5. Stool: This is an optional part of the study. You will provide a sample of stool using a specialized,
sterile tube with a Q-tip type cotton swab. This will simply require you to twirl the end of the
swab in a piece of used bathroom tissue, sealing it in the test tube and placing in your freezer.
Only a small sample is required, and this can be collected at any time of day.
6. Hair: This is an optional part of the study for which you will be compensated if you choose to
participate. As long as you have at least 3cm of hair on your head, we will cut approximately 100
hairs from the back of your scalp in a manner that minimizes any obvious physical change in your
hair style using sterile scissors. This will be done by a member of the research team, and will only
be done once at the beginning of the study.
We are collecting saliva samples in order to analyze the levels of specific proteins, which we are calling
“biomarkers”, that are typically present in the body and that may change during times of stress.
Specifically, these are classed broadly as the stress hormone cortisol, the gonadal hormone testosterone,
and immune or inflammatory markers that are referred to as ‘cytokines’. Stool samples, on the other
hand, will provide us with specific information regarding the different bacterial populations that inhabit
your intestines. The types of bacteria in your intestines may be influenced as a result of significant
stressors, such as trauma or injury. We will be looking to see if any major shifts in the types of bacteria
occur in your system as you are recovering. There is some research that suggests certain genes play a role
in the speed and effectiveness of recovery from an injury. The blood is being drawn primarily for
exploratory and data redundancy reasons. If the other tissues/fluids fail for any reason, the blood will
allow us to evaluate the same chemical markers without having to reconnect with you to collect more
data. Finally, from your hair we will be able to determine the presence of different hormones that have
been stored in your hair from the time before your injury.
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It is important to understand that everyone’s body is different and it’s currently difficult to say what is
‘good’ or ‘bad’ in these analyses. For that reason, these tests should not be considered diagnostic of any
specific diseases or conditions.
Once all samples have been collected, contact the research team at Western University. These samples
will then be retrieved from you by a member of the research team at a day, time and location that is
convenient for you. A subset of the questionnaires will be completed again at 1 month intervals
(approximately 10 minutes to complete), and the biological samples will be collected at 3 and 6 months.
After the 6th month, your participation in the study is complete.
What are the risks and benefits of participating?
There are no immediate anticipated benefits to you from participating in this study. If you request it, we
will provide you with the results of the different system tests that we conduct, although they may be
difficult to interpret in isolation until the rest of our data have been collected. However, if our predictions
are correct and we are able to identify dysfunction in key systems that can explain at least part of the pain
experience, this may open new avenues to treatment that may have benefit to you or others in the
future.
All participants may receive a final report of the study in which the results (using only group data) will be
presented. If you wish to receive this report, you will need to indicate this on the consent form and
include contact information to which the report should be sent. Those participants who wish to receive
their own individual results will be required to contact the Lead Researcher Dr. David Walton directly to
make that request. His contact information can be found at the end of this letter. Keep in mind that the
data associated with this study is not a medical record and shouldn’t be used as such. We will keep the
Master List that links your name with your ID number for 6 months after your completion of the study
after which it will be shredded for confidentiality and privacy protection reasons. This means that we will
not be able to provide your individual results beyond 1 year from your injury.
The risks to participation are minimal and are largely inconveniences due to time. The salivette (saliva
collection tube with cotton swab) samples must be performed at three separate times throughout a single
day which may be a mild disruption to your daily routine for that day. Improper collection and handling of
stool samples MAY pose a risk of bacterial contamination/infection, however, if carefully performed
(including washing your hands afterwards), this risk is quite minimal. The blood will be drawn using a
standard protocol that you have likely experienced before in a doctor’s office or the Red Cross.
Completion of the questionnaires may lead to some people experiencing emotional distress, especially
those that ask you to recall and reflect upon childhood experiences if yours were not positive. We have
provided suggestions for managing emotional distress, should you experience it, at the end of this letter.
We will do everything in our power to ensure your data, including the biological specimens and your
questionnaires, are kept secure and confidential. However, we cannot guarantee against a data breach
regardless of how good our physical and virtual security is. Your data will be stored with only a random ID
number in order to mitigate any potential risk, nonetheless the risk of data breach or loss is possible and
we want to ensure you’re aware of this. Should this happen you will be quickly informed.
Will I be compensated for my participation?
You have different options for the degree to which you wish to participate in this study. The minimum
level of participation is to complete the paper forms, saliva, and blood draw. This would be done once
when you enter the study, then at 1, 2, 3, 6 and 12 months later. Each follow-up will likely take about 45
minutes of your time, and you will receive $30 total for participating in this level of the study. The hair
and stool are optional components, and for each one you will receive an additional $15 ($30 for both).
We recognize that collecting these samples is no small commitment, but can be completed in its entirety
in a single day and a total anticipated time commitment of approximately 1 hour at each collection
period. Out of respect for your time, you will be therefore be reimbursed a minimum of $180 total for
participating in each phase of this study (intake and 1, 2, 3, 6, and 12 months). If you complete the two
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additional components you are eligible for an additional $30 per session, up to an additional $180 for the
entire study.
Who will have access to my information?
A unique randomly-generated 6-digit ID number will appear on all forms belonging to you for the sole
purpose of connecting all of the data you provide at each period. The lead researcher at Western
University, Dr. David Walton, will collect all of the data provided by all participants and will analyze it as
an anonymous group. Once transcribed, all data are stored on the secure, password protected and
firewalled server of Western University and the paper forms are shredded. Western University’s REB and
representatives from Lawson’s Quality Assurance and Education Program will have access to participant’s
data to ensure that it is following the proper laws and regulations. Outside of these groups, your specific
information will not be shared with anyone without your express written consent to do so.
Note some of the tools to be completed are meant to measure severity of symptoms related to
depression or anxiety. IF your responses lead to a score that is suggestive of either depression or anxiety,
your family doctor will be contacted to inform him/her of the results of the scale and what they may
mean. It will ultimately be up to your family physician to decide how and when he/she should follow up
with you if at all.
Data will be retained in anonymous form indefinitely as an ongoing database.
Voluntary participation
Participation in this study is voluntary. You may refuse to participate, refuse to answer any questions or
withdraw from the study at any time. If you choose to withdraw from the study, you may request to have
your contributions to that point removed, at any time up until 6 months after you are done the study.
Withdrawal from the study or refusal to participate is your decision, and may be done without the
requirement of explanation on your part. Withdrawal will in no way affect your current or future
relationship with any of the research team or clinicians associated with the study.
What if I want more information?
You may contact the lead researcher, Dr. David Walton, at Western University (London, Canada) if you
require any further clarification. If you have any questions about your rights as a research participant or
the conduct of the study you may contact the Office of Research Ethics. You are encouraged to keep this
letter of information for your own records.
If you wish to receive a summarized copy of the results of this study and/or your individual results, you
may leave your email address on a separate sheet. The sheet will be held by the research coordinator,
and the email addresses will only be used to provide the results, after which the list will be destroyed.
We thank you in advance for considering participation in this study. You do not waive any legal rights by
signing this consent form.
Sincerely,

David Walton BScPT, PhD
Lead Researcher

Co-researchers:
Ruth Lanius MD PhD
Stan Van Uum MD, PhD
Greg Gloor PhD
Walter Siqueira DDS, PhD
Melanie Colombus
Kristine Van Aarsen
Joshua Lee
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If you are experiencing emotional distress:

This research study does NOT include treatment recommendations. However, while completing the
questionnaires about your emotional state or past experiences, you may find that you experience
emotional distress (e.g. sadness or anxiety) by virtue of thinking about and answering the questions. If
this should happen, it is most commonly short-lived and may be a sign to take a break from the
questionnaires until you settle down enough to come back to them.
However, in the distress can last longer than a day or can be quite severe in some people. If this happens
to you, you are encouraged to seek professional assistance to help deal with your emotional state. The
Canadian Mental Health Association includes several resources on their website as a good place to start:
http://www.cmha.ca/mental-health/find-help/. TeleHealth Ontario can also offer support or direction,
they can be reached 24 hours, 7 days per week. The London Mental Health Crisis Service offers 24-hour, 7
days per week support to those in acute mental distress. Finally, if you feel you are in significant
emotional distress and require more immediate help, you can call your family doctor or emergency
services (9-1-1). In that case you should refrain from completing any further questionnaires and let the
researchers know that you are unable to continue.
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January 9, 2015
Consent form
Modeling recovery from traumatic injuries
Principal Investigator: Dr. David M. Walton PT PhD
I have read the letter of information, have had the nature of the study explained to me and I agree to
participate. All questions have been answered to my satisfaction. I also consent to being contacted by the
Lead Researcher in the case any of my scale scores suggest possible problems with depression or anxiety.
Please indicate the level of study participation to which you are consenting by placing a check in the
appropriate circle:
⃝ Paper forms only (monthly forms, approximately 10 minutes each, $25 total compensation)
⃝ Paper forms and biological specimens but not hair (saliva, stool, serum) at intake, 3 and 6 months
(approximately 1 hour each), paper forms at 1, 2, 4, and 5 months (approximately 10 minutes each). $100
total compensation
⃝ Paper forms and biological specimens including a sample of about 100 hairs from the back of your head
at intake. Other data and intervals as described directly above (approximately 10 minutes in months 1, 2, 4
and 5, approximately 1 hour in months 3 and 6). $125 total compensation.

__________________________________
Participant name (print)
________________________________________________
Participant signature

__________________
Date

________________________________________________
Person obtaining consent (print)
_________________________________________________
Signature of person obtaining consent

__________________
Date
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Request for Summary of Results
⃝ I would like to receive a copy of the group average results from this project (Note: these results will not
have any clinical application and will not affect your medical treatment)
If you would like to receive a copy of the group results, please provide your preferred method of delivery:
⃝ Electronic (email); Email address: ________________________
OR
⃝ Postal mail; Mailing address (incl. Street, City, and Postal code):
_____________________________________
_____________________________________
_____________________________________
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Appendix C: SYMBIOME data collection flow diagram
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Appendix D: Simple Schematic of Moderator Variables

Moderator variables provide key context that can change both the magnitude and direction of the
relationship between the independent variable (one of the 8 biomarkers) and the dependent variable (painrelated outcomes of severity and interference). The implications of these moderators are that biomarkers
may behave differently in the context of pain-related outcomes depending on which metadata subgroup is
being analyzed.
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Appendix E: Conceptual Summary Figure

Tissue trauma can occur in the peripheral tissues (affecting primary afferent pathways) or spinal tissues
(affecting secondary afferent pathways) resulting in an immune inflammatory repair response.
Inflammatory factors (TNF-α, IL-1β, IL-6, IL-10, TGF-β1, and CRP) can affect neural activity of tissues which
include increased noxious signaling (hyperalgesia) and heightened sensitivity to benign stimuli (allodynia).
Inflammation can also affect sensitivity of second order WDR neurons resulting in increased sensitivity
and neurological drive in the spinal cord. Cortisol, TGF-β1, and in particular, BDNF may be implicated in
their ability to facilitate the long-term synaptic plasticity in spinal afferents that results in chronic
sensitization. Progressing from peripheral to central signaling, IL-1β and IL-6 may be involved in
facilitating fear-learning and fear-memory in the context of stress. This may contribute to the associative
mechanism between trauma, fear, adaptation and learning. TGF-β1 and BDNF are associated with growth
arrest and DNA damage enzymes (Gadd45) which have been implicated in a number of different
psychiatric diseases. All of the above mentioned mechanisms have been previously described in the
literature and cited throughout chapters 2, 3, and 4 of this dissertation.
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Higher level cortical plasticity in the brain (from Mansour et al. 2014)1 – Acute pain evokes nociceptive
pathways (solid arrows) in the brain which involves the thalamus (Thal), parabrachial nucleus (PB),
amygdala (Amyg), insula (Ins), anterior cingulate cortex (ACC), and 1° and 2° somatosensory regions (S1
and S2). Under normal circumstances, these nociceptive associations dissipate with time. Prolonged
stimulation can result in the transition towards chronic pain and “emotional suffering” which involves
higher brain regions that generate our motivation and sense of self (dotted arrows) including the basal
ganglia (BG), pre-frontal cortex (PFC), and 1° motor cortex (M1). This transition leads to the persistence
of memory with regard to pain, thereby perpetuating the experience.
1. Mansour AR, Farmer MA, Baliki MN, Apkarian AV. Chronic pain: the role of learning and brain plasticity. Restorative neurology
and neuroscience. 2014 Jan 1;32(1):129-39.
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